The Role of Extracellular Matrix and Matrix-Degrading Proteases in Neonatal Hypoxic-Ischemic Injury by Leonardo, Christopher C
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
6-5-2008
The Role of Extracellular Matrix and Matrix-
Degrading Proteases in Neonatal Hypoxic-
Ischemic Injury
Christopher C. Leonardo
University of South Florida
Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons, and the Neurosciences Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Leonardo, Christopher C., "The Role of Extracellular Matrix and Matrix-Degrading Proteases in Neonatal Hypoxic-Ischemic Injury"
(2008). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/359
  
 
The Role of Extracellular Matrix and Matrix-Degrading Proteases in Neonatal  
Hypoxic-Ischemic Injury 
 
by 
 
Christopher C. Leonardo 
 
 
A dissertation in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Molecular Pharmacology and Physiology 
School of Biomedical Sciences 
College of Medicine 
University of South Florida 
 
 
Major Professor: Keith R. Pennypacker, Ph.D. 
Marcia N. Gordon, Ph.D. 
John R. Hassell, Ph.D. 
Alison E. Willing, Ph.D. 
 
 
 
Date of Approval: 
June 5, 2008 
 
 
 
 
Keywords: lectican; matrix metalloproteinase; hypoxia; ischemia; neonate; inflammation; 
migroglia; macrophage 
 
 
© Copyright 2008, Christopher C. Leonardo 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Note to the reader: The original of this document contains color that is necessary for 
understanding the data. The original dissertation is on file with the University of South Florida 
library in Tampa, Florida 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Dedication 
This dissertation is dedicated to all of the individuals whom, through 
tireless efforts and extraordinary insights, have contributed to the progress 
of scientific discovery. 
 
 
 
 
 
 
 
 
 
 
 
  
 
ACKNOWLEDGEMENTS 
 I would like to acknowledge all those who have contributed in some fashion to the 
completion of this work. I would first like to thank my mentor, Dr. Keith R. Pennypacker, not only 
for all of his intellectual contributions and support, but also for accepting me into his laboratory 
after the departure of my previous mentor. In this regard, I would also like to acknowledge Dr. 
Bruce G. Lindsey for providing me with the necessary funds required to complete this work. I 
would like to thank my previous mentor Dr. Paul E. Gottschall for all of the scientific knowledge 
that he has imparted onto me, and for providing the initial intellectual foundations upon which this 
project was developed. I would also like to thank Dr. Alison E. Willing, with whom I have enjoyed 
collaborating. Although this is an individual work, I would like to recognize all of my colleagues 
who have contributed not only to the intellectual pursuit of the questions raised in this work, but 
also to the meticulous experimentation that was required to collect these data, including: Dr. 
Joanne Ajmo, for providing significant intellectual contributions and training in various technical 
procedures that led to the completion of this work; Dr. Craig T. Ajmo, for providing assistance with 
the carotid artery ligation technique that led to the completion of aims 1 and 2; Aaron A. Hall, for 
his intellectual contributions and training in tissue culture techniques used for aim 3; and all other 
laboratory personnel, including Autumn K. Eakin, Lisa A. Collier and Michelle M. Hamel, for their 
technical contributions and support. Finally, I would like to extend a special thank you to all of my 
family and friends for providing encouragement and support throughout this endeavor. 
 i
 
 
 
TABLE OF CONTENTS 
List of Figures                       v 
Abstract                       vii 
Background and Significance                   1  
Perinatal Hypoxic-Ischemic Brain Injury                           1  
Clinical Pathology                  1 
  Rodent Model of Hypoxia-Ischemia                            2 
  Behavioral Paradigms Used in Rodent Models                          3 
  Selective Vulnerability of pre-Oligodendrocytes                          4 
 Extracellular Matrix in the Developing Brain                  6 
  The Lectican Family of Chondroitin Sulfate Proteoglycans                        6 
  Lectican Expression in Developing White Matter                                      8 
  Extracellular Matrix-Degrading Proteases                          8 
  Growth Factor Substrates for Matrix Metalloproteinases                                   12 
  Endogenous Inhibitors of Matrix Metalloproteinases                       13 
 Cellular Responses to Hypoxia-Ischemia              13 
  The Early Response                           13 
  Neuroinflammation: The Secondary Response                        15 
 Matrix Metalloproteinases and Cerebral Ischemia             17 
  Blood Brain Barrier Degradation                          17 
  Sheddase Activity and Extracellular Matrix Remodeling                                   18 
 Extracellular Matrix, Matrix Metalloproteinases and  
      Hypoxia-Ischemia: The Big Picture                19 
  References                23 
 
 ii
Chapter 1: Versican and Brevican are Expressed with Distinct Pathology of Neonatal  
Hypoxic-Ischemic Injury                                   34 
 Abstract                               35 
 Introduction                             36 
 Materials and Methods                                        37 
  Induction of Hypoxia-Ischemia                                      37 
  Perfusion and Tissue Preparation                         38 
  Histology and Immunohistochemistry                                     39 
  O4 Sulfatide Quantification                          39 
  Statistical Analyses                           40 
 Results                                          40 
  Progressive Lesion after H-I                                      40 
  Reactive Gliosis and Apoptosis in White Matter                                    41 
  Brevican Deposition is Associated with Lesion                        
Progression in Gray Matter              42 
  Versican is Differentially Expressed in    
Gray and White Matter               43 
  White Matter Loss after Hypoxia-Ischemia                                    44 
 Discussion                             45 
 References                             63 
 
Chapter 2: Delayed Administration of a Small Molecule MMP Inhibitor  
Protects the Neonatal Rat Against Hypoxic-Ischemic Brain Injury                       66 
 Abstract                             67 
 Introduction                             68 
 Materials and Methods                                        70 
  Induction of Hypoxia-Ischemia                                      70 
  Drug Treatment                                        71 
 iii
  Tissue Preparation                           71 
  Histology and Immunohistochemistry                                     72 
  Image Analyses and Quantification                                     73 
  Statistical Analyses                           73 
 Results                                          74 
  Microglia/macrophages at cortical lesion site                                    74 
  Cell Death is Associated with MMP-Cleaved Versican  
and microglia/macrophage recruitment             75 
  Delayed Treatment Dampens Reactive Astrogliosis                                   75 
  Delayed Treatment Reduces Cell Death                                     76 
  Delayed Treatment Ameliorates the  
Microglia/Macrophage Response              77 
 Discussion                                         77 
 References                                         94 
 
Chapter 3: Inhibition of Gelatinase MMPs Reduces Neurodegeneration in an  
Ex-Vivo Model of Oxygen Glucose Deprivation                 99 
 Abstract                                       100 
 Introduction                                       102 
 Materials and Methods                                                  104 
  Organotypic Slice Culture                                    104 
  Oxygen Glucose Deprivation                                                105 
  Histology and Immunohistochemistry                                               106 
  Fluoro-Jade Staining                                                 107 
  In Situ Zymography                                     107 
  Image Analyses and Quantification                                               107 
  Statistical Analyses                                     108 
 
 iv
Results                                                    108 
  Cellular Localization of MMP-9                                                108   
Treatment with AG3340 or Minocycline  
Attenuates Gelatinase Activity            109 
  Treatment with AG3340 or Minocycline  
Reduces Neurodegeneration                        110 
 Discussion                                       111 
 References                                       127 
 
Conclusions                  132 
Brevican and Versican Deposition after H-I                       133 
 ADAMTSs, Lectican Turnover and Pre-OL Susceptibility to H-I                                 137 
 The Effects of Anti-Inflammatory and MMP-Inhibitory                       
 Compounds in vivo              138 
MMP Activity in Brain Contributes to Injury in the Absence of                      
Peripheral Leukocytes              143 
 Implications and Future Directions             145 
 References               159 
                           
About The Author                     166 
 
 
     
 
 
 
 
 
 v
 
 
 
LIST OF FIGURES 
Chapter 1 
Figure 1. Rat brain regions selected for immunohistochemistry                                    49 
Figure 2. P7 H-I produces progressive lesions with variable severity                       51 
Figure 3. Apoptosis and reactive gliosis after hypoxic-ischemic insult                                   53 
Figure 4. Brevican deposition is associated with lesion progression                       55 
Figure 5. Versican exhibits a unique expression profile with lesion progression          57                     
Figure 6. White matter loss after hypoxia-ischemia                         59 
Figure 7. Quantification of external capsule white matter loss                        61 
 
Chapter 2 
Figure 1. Anti-PLPDSR                             82 
Figure 2. Microglia/macrophages are present with MMP-cleaved  
versican at cortical lesion site                           84 
Figure 3. Cell death is associated with MMP-cleaved versican and 
microglia/macrophage recruitment                                   86 
Figure 4. Delayed treatment dampens reactive astrogliosis                        88 
Figure 5. Delayed treatment reduces cell death                          90 
Figure 6. Delayed treatment ameliorates microglia/macrophage response                                  92 
 
Chapter 3 
Figure 1. Basal MMP-9 expression                         115 
Figure 2. Neuroinflammatory response to oxygen glucose deprivation                                 117 
Figure 3. Gelatinase activity is elevated after oxygen glucose deprivation                                 119 
Figure 4. Quantification of in situ zymography                        121 
 vi
Figure 5. Neurodegeneration occurs after oxygen glucose deprivation                                 123 
Figure 6. Quantification of Fluoro-Jade staining                        125 
 
Conclusions 
Figure 1. ECM lecticans and gelatin-degrading MMPs contribute to                                            
neonatal H-I injury through multiple mechanisms            151 
Figure 2. Inhibition of gelatin-degrading MMPs reduces the inflammatory                                   
response and improves the neuropathological outcome after  
H-I in the rat neonate                                      153 
 
Supplemental Figure 1. Activated microglia/macrophages recruit to the                                
cortical lesion site 24 hrs after H-I                                                                                         155 
Supplemental Figure 2. MMP-9 expression increases 24 hrs after H-I                                       157                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
 
 
 
ABSTRACT 
 Improvements in medical care over recent decades have increased the number of 
premature and low birth weight infants that survive hypoxic-ischemic (H-I) insults. Because there 
is a rising incidence in diseases associated with these events, it is critical to develop effective 
therapies to treat the various resulting neuropathies. Extracellular matrix constitutes the majority 
of brain parenchyma. Lecticans and matrix-degrading proteases including ADAMTSs (a 
disintegrin and metalloproteinase with thrombospondin repeats) and matrix metalloproteinases 
(MMPs) exert effects on cell viability and may be associated with either protective or destructive 
processes after H-I. Both ADAMTSs (Cross et al. 2006; Tian et al. 2007) and MMPs (del Zoppo et 
al. 2007; Gu et al. 2005; Rosenberg et al. 2001) have been associated with pathological states in 
brain, yet the relative contributions of lecticans, ADAMTSs and MMPs to inflammation and cell 
death remain unknown.  
 In the present study, the first series of experiments were conducted to characterize 
cellular damage and neuroinflammation in the postnatal day 7 rat after exposure to H-I, and to 
determine if cell death and inflammation were associated with alterations in lectican expression. 
Data showed that reduced brevican expression occurred 4 days after H-I in lesioned 
hippocampus. Additionally, reduced versican expression in white matter was concomitant with 
pre-OL cell death at this endpoint. In contrast, both lecticans were elevated at later endpoints (14, 
21 days) that were associated with increased neuroinflammation and cavitary infarction. These 
data suggest that lectican loss is associated with cell death at the early endpoint, whereas 
increased lectican deposition over time likely leads to glial scar formation and a reduced capacity 
for neuroplasticity.  
 Two subsequent series of experiments were conducted to determine the relative 
contributions of matrix-degrading proteases to injury, and whether proteolytic activity was 
associated with neuroinflammatory events. The first objective was to determine whether 
 viii
treatment with AG3340, a selective inhibitor of gelatin-degrading MMPs, or the anti-inflammatory 
compound minocycline, could provide neuroprotection when administered at a delayed time point 
after insult, and to compare the efficacy of AG3340 with that of the well-known anti-inflammatory 
compound minocycline. Data showed that both compounds effectively dampened the recruitment 
of microglia/macrophages to the lesion site when administered 24 hrs after H-I. These effects 
were associated with reduced neurodegeneration, indicating that these compounds neuroprotect 
at a clinically relevant time point. The final series of experiments tested whether these 
compounds could neuroprotect in an ex vivo model of oxygen glucose deprivation (OGD) that 
lacks peripheral immune cell involvement, thus providing insight into the relative contributions of 
resident microglia and gelatinase activity to the inflammatory sequelae. Results showed that both 
compounds blocked the OGD-induced increase in gelatinase activity and were neuroprotective in 
the absence of peripheral immune cells. Taken together, these data indicate that resident 
microglia contribute to H-I injury through gelatinase activation. Thus, the present study 
demonstrates that gelatin-degrading MMPs are important targets to consider when developing 
therapies to combat neonatal H-I injury. 
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Background and Significance 
Perinatal Hypoxic-Ischemic Brain Injury: 
Clinical Pathology 
 Due to improvements in medical care over past decades, increasing numbers of 
premature and low birth weight infants survive the neonatal period. Not surprisingly, there has 
been a rise in the incidence of diseases associated with prematurity, including neuropathies. 
Advances in diagnostic methods for these neuropathies and general knowledge of the cellular 
and molecular consequences have provided insight into potential causes for potential candidate 
therapeutics. Hypoxia-ischemia (H-I) is thought to be a major cause of perinatal brain injury, 
producing lesions of variable severity including focal necrotic cell death, diffuse white-matter 
injury, and cystic or cavitary infarction. It is estimated that nearly 40% of premature infants may 
suffer from either intraventricular-periventricular hemorrhage or periventricular lesions. In both 
cases, age of prematurity and birth weight are associated with increased risk, with younger, 
lighter infants at highest risk (du Plessis and Volpe 2002).  
The escalating incidence of these deficiencies and lack of effective therapies 
underscores the importance of research in this area. Perinatal brain injury has been attributed to 
impaired modulation of systemic blood pressure by an immature vascular system. The immature 
vasculature and low baseline blood flow render the periventricular brain highly vulnerable to even 
modest changes in perfusion pressure (Baier 2006). The resulting lesions range from dilated 
ventricles in mild cases to focal, cystic infarcts or cavitations in severe cases. This particular 
injury is associated with high risk for subsequent development of cerebral palsy (CP), a spastic 
motor condition that is often accompanied by learning deficits. Though less common in the term 
infant, perinatal brain injury is typical in preterm infants born with spastic diplegia, the most 
common form of CP (70 - 80% of patients) in which both legs are affected. An important clinical 
study revealed that oligodendrocyte precursor (pre-OL) proliferation and differentiation are 
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coincident with the developmental period (~23-32 gestational weeks) during which preterm 
infants are most vulnerable to H-I injury (Back et al. 2001). Since that time, a growing body of 
literature has emerged indicating that white matter pathology observed in response to H-I is 
directly related to the selective vulnerability of pre-OLs, resulting in lower numbers of mature OLs 
and compromised myelination in the adult (Back et al. 2002; Craig et al. 2003; Skoff et al. 2001). 
While white matter damage has clearly been shown to produce motor disturbances, other 
mechanisms account for distinct forms of pathology. Cognitive deficits associated with H-I injury 
also result from damage to fiber tracts in white and gray matter. This neurodegeneration occurs 
not only through disrupted myelination but also in response to deleterious biochemical cascades 
that are activated after the insult. For example, there is strong and convincing evidence 
supporting the roles of oxidative stress and free radicals (Back et al. 1998; Elibol et al. 2001; 
Ferriero et al. 1996; Jian Liu and Rosenberg 2005). These mechanisms contribute to cell death in 
both neurons and glia, demonstrating the complexity of this pathology. Indeed, most perinatal H-I 
injuries manifest later in development as motor disturbances accompanied by some degree of 
cognitive dysfunction that occurs as a result of neurodegeneration. 
 
Rodent Model of Hypoxia-Ischemia 
 The most common experimental animal model currently used to recapitulate human 
perinatal H-I was originally developed by Levine (Levine 1960) and reprised by Vannucci and 
colleagues for use in the neonate (Rice et al. 1981; Vannucci et al. 1999). In this model, unilateral 
ligation of the common carotid artery is performed in the neonatal rat followed by transient (hours) 
exposure to hypoxia. The resulting pathology includes injury to cerebral white matter (Back et al. 
2002; McQuillen and Ferriero 2004) and gray matter (Almli et al. 2000; Arteni et al. 2003; Rice et 
al. 1981; Towfighi et al. 1995; Vannucci et al. 1999), both of which are likely to result in loss of 
cognitive and motor function (Bona et al. 1997; Ikeda et al. 2001; Jansen and Low 1996; Young 
et al. 1986). Importantly, lesions mimic those observed in perinatal brain injury, including 
ventricular dilation, cerebral white matter infarctions and substantial neuronal cell death. A key 
feature that is relatively unique to this rodent model, however, is shrinkage or elimination of 
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hippocampal structure in the severely injured brain (Aya-ay et al. 2005). Although there is 
inherent variation in this model in terms of lesion severity, it has proven quite useful for 
investigations into the cellular and molecular consequences of H-I. Subsequent sections will 
primarily address knowledge accumulated from experimental rodent studies, as the Vanucci H-I 
model was used to collect the majority of the data contained within this dissertation. 
 
Behavioral Paradigms Used in Rodent Models 
 A host of investigations have tested the efficacy of various therapeutic agents in 
improving neurohistological outcomes after H-I (du Plessis and Volpe 2002; McQuillen and 
Ferriero 2004; Vannucci et al. 1999). The ultimate proof of therapeutic efficacy, however, is 
improvement in sensorimotor function. An early study by Young and colleagues documented 
sensorimotor deficits in rat that resulted from H-I insult (Young et al. 1986), consistent with 
cognitive and motor deficits in the clinical population. Despite these data, little was accomplished 
to further assess behavioral deficits in the H-I model for quite some time. Recently, behavior has 
been revisited in efforts to bring external validity to animal models, demonstrating motor and 
cognitive deficits associated with H-I events (Arteni et al. 2003; Bona et al. 1997; Ikeda et al. 
2001; Jansen and Low 1996). Furthermore, administration of brain-derived neurotrophic factor  
prior to (Almli et al. 2000) or insulin-like growth factor-1 shortly after (Guan et al. 2003) H-I have 
been shown to improve behavioral outcomes in rat. A subsequent study obtained similar results 
in mouse (Ten et al. 2003). In terms of the clinical condition associated with H-I, however, injury is 
generally not detected until much later when the behavioral manifestations appear. Therefore, 
although the data from animal studies were encouraging, the need for therapeutics that can be 
delivered at delayed time points is essential in treating patients affected by H-I.  
 Although the physical handling of neonates introduces a unique set of concerns 
regarding alterations of normal developmental processes, the data that can be obtained from 
behavioral batteries is essential to understanding the ultimate consequences of brain pathology. 
The fields of neurodevelopment and developmental biology have constructed useful tests of 
sensorimotor and cognitive functions that maintain reliability across species. Developmental 
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neuronal cell death via anoikis, the process whereby cells die due to the loss of critical signaling 
with the surrounding microenvironment (Grossmann et al. 2001). In contrast to the adult brain, the 
neonatal brain contains immature cerebral white matter. The active myelination period occurs 
disabilities are assessed through observations of simple reflex behaviors, each of which 
represents a unique developmental milestone (Jansen and Low 1996). Neuromuscular deficits 
are often measured with the vertical pole test, one which exploits the requirements of grip 
strength and balance to orient the body and remain suspended in an inverted manner. Perhaps 
the most well-known behavioral assay is the open field test in which spontaneous locomotor 
activity is measured and recorded over some duration, typically after several habituation trials. 
The activity is then quantified either using the classical method of counting photocell beam breaks 
or with more recent technologies, such as video surveillance that sends a live digitized signal to a 
computer template with preset distance parameters and continuously records movement. 
 
Selective Vulnerability of Pre-oligodendrocytes  
 Pre-OLs arise from cells in the subventricular zone  of the lateral ventricles, where they 
proliferate, differentiate and migrate to regions composed of white and grey matter (Levison and 
Goldman 1993). In neural tracts, OLs are responsible for the myelination of axons. Myelination 
provides the framework for saltatory conduction, thus allowing for fast and efficient signal 
propagation throughout the CNS. In the perinate as well as in the adult, H-I insults produce white 
matter disturbances that can lead to cognitive and motor deficits. Several lines of evidence 
indicate that injury occurring after adult stroke, for example, is due to disruption of axoglial 
junctions. The adult brain exhibits complete myelination of neural tracts. The junctions formed 
between neuronal axons, astrocytes and the myelin sheaths of oligodendrocytes form an 
interface that aids in maintaining structural stability while allowing for the communication of 
signals obtained from sampling the extracellular space. Studies indicate that degradation of 
myelin proteins, such as myelin basic protein and myelin associated glycoprotein, compromises 
these junctions. After this occurs, neurons may not function at full capacity due to the loss of 
efficacy in signal propagation. Others have suggested that cleavage of myelin proteins leads to 
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from ~postnatal day 7 (P7) to ~P21. White matter injury in the neonate less likely results from 
degradation of myelin proteins or disruption of axoglial junctions since these junctions are still 
being formed and myelination is at an early stage. In fact, to achieve effective myelination, OL 
progenitors must complete a maturational process. Throughout maturation, OLs differentiate into 
several distinct phenotypes prior to achieving the capacity to myelinate axons. The recognition 
that different OL phenotypes may predominate during specific stages of early development raised 
the intriguing possibility that the susceptibility of OLs to H-I injury may depend upon the specific 
maturational state of these cells.   
As the specific stage of differentiation was potentially a crucial determinant of underlying 
susceptibility to H-I, a detailed study of OLs at each developmental stage was imperative. The 
ability to distinguish between distinct biological phenotypes within the OL lineage has been aided 
by the recognition that OLs express and cease to express specific antigens throughout 
differentiation. An elegant series of experiments by Reynolds and Hardy determined through 
combined data from OL cultures and whole tissue sections that the O4 antigen is a cell surface 
marker for both pre-OLs and mature OLs in rat, while galactocerebroside (GC) labels proliferating 
and myelinating OLs; O4+/GC+ cells are mature, non-mitotic and differentiated. In addition, the 
NG2 proteoglycan appears to be a reliable marker for pre-OLs (Reynolds and Hardy 1997). 
These data suggest that NG2+/O4+/GC- cells are likely to be either pre-OLs or immature OLs, a 
distinction that remains somewhat ambiguous and unresolved. Taken together, these data 
suggest that as pre-OLs begin to express the O1 antigen, they begin to differentiate into 
immature, non-mitotic cells and gain resistance to H-I. Further differentiation of immature OLs to 
mature, myelinating cells is accompanied by the surface expression of myelin markers. The 
characterized cell surface antigen profile for each biological phenotype is as follows; pre-OL 
(NG2+/O4+/O1-/GC-), pre-OL/immature OL (NG2+/O4+/O1+/GC-), mature OL (NG2-
/O4+/GC+/MBP+).  
Since that time, Stephen Back’s laboratory has completed an investigation of OL lineage 
progression in both rodent and in human in efforts to match the period of rodent white matter 
development with that of the human during the critical period of vulnerability. Data from these 
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experiments revealed that pre-OLs predominated at P2 in the rat corpus callosum, a white 
matter-rich region in brain. By P7, the majority of these cells had differentiated into immature OLs 
that expressed the O1 antigen. Therefore, it seemed likely that the pre-OLs present at P2 most 
closely resembled those that predominate during the period of vulnerability in human. Mature 
OLs, immature OLs and early progenitors were resistant to H-I (Back et al. 2001; Craig et al. 
2003). Despite these data, other investigations into the mechanisms of neonatal H-I injury have 
been performed in the P7 rat. These studies have shown that developing OLs are susceptible to 
injury at this age (Aya-ay et al. 2005; Follett et al. 2000) and are similar to the phenotype that 
predominates in the human during the critical period of susceptibility, thus validating the window 
between P2 and P7 as a reasonable period to study pre-OL injury resulting from H-I. It is 
important to note that while OLs differentiate into the mature phenotype as they migrate to their 
targets, little is known regarding functional differences between the immature phenotypes. 
 
Extracellular Matrix in the Developing Brain: 
The Lectican Family of Chondroitin Sulfate Proteoglycans 
 Extracellular matrix (ECM) is widely distributed throughout the brain parenchyma. ECM 
proteoglycans subserve many functions that are imperative to cell viability. As such, ECM 
turnover in response to injury influences the potential for plasticity and repair. Matrix in brain is 
composed primarily of chondroitin sulfate proteoglycans (CSPGs) that aggregate with the linear 
polysaccharide hyaluronan to form structural lattices (Rauch 2004). Lecticans are a family of 
CSPGs consisting of aggrecan, neurocan, versican and brevican. Constituting the preponderance 
of ECM in the brain, lecticans provide structural support and modulate cell signaling, migration 
and neurite outgrowth (Yamaguchi 2000). These PGs are characterized by structurally conserved 
globular domains at the N and C termini, as well as central chondroitin sulfate glycosaminoglycan 
(CS-GAG) – binding domains. GAGs are repeating disaccharides composed of glucuronic acid  
and N-acetyl galactosamine. These disaccharides are sulfated in the Golgi apparatus by 
chondroitin sulfotransferases. The specific positions and patterns of sulfation influence GAG 
binding properties, and therefore largely determine lectican function. Lecticans are well known 
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inhibitory substrates to neuroplasticity and repair (Beggah et al. 2005; Jones et al. 2003a; Jones 
et al. 2003b).GAG chains link to serine residues within the central domain of the core protein via 
xylose, catalyzed by the enzyme xylotransferase, and increase the inhibitory properties of 
lecticans (Silver and Miller 2004). The central GAG-binding domains are structurally diverse 
throughout the family and contain varying numbers of GAG attachment sites (aggrecan: ~120; 
versican: ~20; neurocan: ~7; brevican: ~3) (Yamaguchi 2000). The N-terminal globular domain 
binds hyaluronan with high affinity. Hyaluronan serves as the backbone of the ECM, containing 
repeating disaccharide units that produce chains up to 25,000 disaccharides in length (Galtrey 
and Fawcett 2007). The C-terminal globular domain contains a C-type lectin-binding domain 
which is thought to associate with tenascin-C or tenascin-R, depending upon the specific 
developmental stage in brain and the particular lectican in question. The substrate specificities of 
these globular domains are crucial in permitting the formation of the ECM lattice (Rauch 2004).   
The expression patterns of lecticans throughout development are temporally unique and 
tissue-specific. In general, brevican and versican are the most ubiquitous in brain. Neurocan and 
brevican appear to be specific to neural tissues, while aggrecan is expressed mainly in 
connective tissues. Brevican and aggrecan exhibit similar expression patterns in brain, steadily 
increasing from ~embryonic day 14 (E14) and reaching plateau at ~P150. Neurocan expression 
rises during the embryonic period, peaking shortly after birth and rapidly declining. To date, 4 
splice variants have been identified for versican. Versican V1 expression is predominantly 
embryonic and is similar to that of neurocan. In contrast, versican V2 expression increases from 
~P10 to P100, similar to that of brevican (Yamaguchi 2000).  
Brevican and versican share common features in that they are both present in high 
abundance in brain and are secreted by glial cell types under developmental regulation. By virtue 
of their discreet, developmental expression and their key roles in neural plasticity, proteolytic 
degradation of brevican and versican V2 may contribute to neuronal cell death and white matter 
injury following ischemic insult. Previous studies have demonstrated elevated CSPG expression 
in the injured adult rodent brain (Beggah et al. 2005; Jones et al. 2003a; Jones et al. 2003b; 
Mayer et al. 2005; Vorisek et al. 2002). The capacity of lecticans to act as non-permissive 
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substrates to tissue remodeling has also been well-documented (Asher et al. 2000; Galtrey and 
Fawcett 2007; Jaworski et al. 1999). Despite these data, little is known regarding the relationship 
between lectican function and neonatal H-I injury.  
  
Lectican Expression in Developing White Matter 
 The glia contained within neural tracts are surrounded by lecticans, particularly brevican, 
neurocan, and versican V2. In the rat hippocampal fimbria (FB) there is little brevican expression 
at the time of birth. During the first 2 postnatal weeks, brevican expression increases in OLs, 
peaking at approximately P14. Brevican expression is subsequently downregulated in OLs, as it 
is taken over by astrocytes by P21. Interestingly, the temporal pattern of brevican expression in 
OLs coincides with the active period of myelination. In adult FB, brevican expression is restricted 
almost entirely to astrocytes (Ogawa et al. 2001). The developmentally regulated expression of 
brevican, coupled with a late transition to expression in astrocytes, suggests that brevican plays 
an important role in the differentiation and proliferation of pre-OLs. Likewise, the rise in versican 
V2 expression that occurs throughout development may also aid in OL differentiation and 
subsequent myelination. Data from a previous study demonstrated reductions in brevican core 
protein, proteolytic fragments of cleaved brevican and NG2+ cells in FB just 4 days after H-I (Aya-
ay et al. 2005), lending further support that brevican may provide survival signals to pre-OLs. It is 
also possible, however, that the reductions in brevican resulted from death of the cells from which 
it was produced. To date, this important question remains unanswered.  
 
Extracellular Matrix-Degrading Proteases  
ECM proteoglycans are important in providing signals to neighboring cells and structural 
integrity to the interstitial space in both normal and pathological states. ECM turnover in brain is 
achieved predominantly through proteolytic cleavage by two major families of matrix-degrading 
proteases; ADAMTSs (Ua U Ud Uisintegrin Ua Und UmUetalloproteinase with UtUhromboUsUpondin motifs) and 
matrix metalloproteinases (MMPs). Both families of enzymes are metalloendopeptidases and are 
members of the metzincin superfamily of zinc-dependent proteases. The term metzincin reflects 
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the zinc ion that is present within the catalytic site, as well as the conserved methionine residue 
downstream of the catalytic site.  
The ADAMTSs are a sub-family of the ADAM proteases. ADAMs are known to participate 
in ectodomain shedding and activation of various cell surface proteins (Seals and Courtneidge 
2003). Though highly conserved structurally, the major difference between these 2 classes of 
molecules is that while ADAMs are primarily transmembrane proteins, ADAMTSs lack the 
transmembrane domain and are secreted into the ECM where they exert their effects. As such, 
these enzymes have an increased capacity to contribute to matrix remodeling and inflammatory 
responses in the injured brain. ADAMTSs are synthesized as inactive, pre-proenzymes. N-
terminal processing of the signal peptide is required for trafficking to the plasma membrane, and 
subsequent cleavage of the pro-domain is necessary to render an activated enzyme. Processing 
of the prodomain occurs in the trans-Golgi network and is achieved most likely through cleavage 
of the furin recognition sequence by the proprotein convertase furin, though other evidence 
suggests the presence of multiple furin recognition sites in addition to a furin independent 
mechanism of activation (Wang et al. 2004). Substrate specificity is conferred via C-terminal 
truncation that occurs predominantly in the spacer regions of the ancillary domains (Apte 2004; 
Porter et al. 2005).  
Substrates of ADAMTSs vary depending upon the specific physiological context and 
protease in question. The effects of substrate binding include growth factor sequestration and the 
proteolytic processing of various ECM proteoglycans (Flannery 2006; Tang 2001). For example, 
ADAMTS1 inhibits angiogenesis by binding to the heparin-binding isoform of vascular endothelial 
growth factor (VEGF-165), thus preventing its binding and subsequent phosphorylation of the 
endogenous receptor VEGFR2 (Luque et al. 2003). ADAMTS4 and ADAMTS5 proteolytically 
process lectican CSPGs including aggrecan (Nagase and Kashiwagi 2003), brevican (Matthews 
et al. 2000) and versican (Sandy et al. 2001). While the cleavage of aggrecan is associated with 
disease states such as rheumatoid and osteoarthritis, brevican and versican processing may 
have relevance to many physiological processes, as they are ubiquitous in brain and their 
expression is developmentally regulated (Yamagata and Sanes 2005; Yamaguchi 2000).  
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Some data exists regarding the potential roles of ADAMTSs in the injured rat brain. 
ADAMTS1 mRNA levels increased 24 hrs after permanent middle cerebral artery occlusion 
(MCAO) and remained elevated up to 21 days after the insult. In contrast, ADAMTS8 transcript 
decreased in the early phase of the injury (Tian et al. 2007). Other data showed alterations in 
ADAMTS message and protein levels after experimental autoimmune encephalomyelitis  (Cross 
et al. 2006), a model producing abherrant myelination similar to that which is observed in multiple 
sclerosis. Despite these data, ADAMTSs are mainly known for their contributions to various 
cancers, skin disorders and arthritic conditions, and while several studies suggest the 
involvement of ADAMTSs in the neural response to injury, ADAMTS cleavage of lecticans did not 
appear to contribute to injury in a neonatal rodent model of H-I (unpublished observations; see 
“Discussion”).  
While the role of ADAMTSs in ischemic injury is unclear, evidence indicates that other 
members of the metzincin superfamily may be important contributors to H-I injury. The MMPs are 
perhaps the most well-studied of the matrix-degrading proteases, yet it remains elusive exactly 
how these enzymes regulate most cellular processes during development and in pathological 
states. The MMPs can be divided into 7 sub-families based on structural homology (minimal 
domain: MMP-7, -26; collagenases, stromelysins and other MMPs: MMP-1, -3, -8, -10, -12, -13, -
19, -20, -27; gelatinases: MMP-2, -9; furin-activated MMPs: MMP-11, -21, -28; membrane-type 
(MT) MMPs: MMP-14, -15, -16, -24; GPI-anchored MMPs: MMP-17, -25; type II transmembrane: 
MMP-23A, -23B). Collectively, these enzymes are capable of proteolytically cleaving all ECM 
proteins (Mott and Werb 2004). MMP and ADAMTS metalloendopeptidases share many 
structural and functional attributes. Like ADAMTSs, most MMPs (with the exception of 
membrane-anchored MMPs) are generally secreted from cells and exert their effects within the 
ECM. These enzymes are synthesized as latent zymogens. The N-terminus contains a signal 
peptide that is cleaved in the secretory pathway, thus targeting it for secretion, while the C-
terminus (a hemopexin-like domain in the majority of MMPs) is most important in determining 
substrate specificity. In addition, cleavage of the propeptide domain is necessary to confer 
enzymatic activity. In contrast to the ADAMTS family, however, MMP activation is achieved via 
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sequential processing of the N-terminus that can occur by several distinct mechanisms, such as 
through the activity of serine proteases or other MMPs, the use of reagents such as sodium 
dodecyl sulfate or 4-aminophenylmercuric acetate, and alterations in temperature or pH. 
Ultimately, activation occurs via activation of a “cystein switch” mechanism, in which a covalent 
bond between an N-terminal cystein residue and the catalytic zinc site is disrupted upon cleavage 
of the cystein-containing prodomain. Furthermore, MMPs are capable of autocatalysis and 
therefore can modify their own proteolytic capabilities (Flannery 2006).  
Several lines of evidence have demonstrated that MMP activity performs critical functions 
in the developing brain. Most importantly, the MMPs play a major role in developmental 
myelination. Data from rodent knockout studies showed that MMP-9 and MMP-12 null mice 
demonstrated reductions in myelination, while MMP-12 null OL progenitor cultures were also 
unable to differentiate into mature cells (Larsen et al. 2003; Larsen and Yong 2004). A series of 
experiments performed by Yong et al. investigated the effects of MMP-9 on OL process extension 
both in vitro and in vivo. Cultured OLs from human, bovine and mouse showed process extension 
concomitant with active MMP-9 expression. Furthermore, OL process extension was reduced 
after treatment with MMP inhibitors or an MMP-9 blocking antibody. Consistent with these data, 
cultures from MMP-9 knockout mice showed reduced process extension relative to non-
transgenic controls (Oh et al. 1999). MMP-9 expression in the mouse corpus callosum, a white 
matter-rich region of brain, also correlated with the postnatal period during which myelination 
occurs (Uhm et al. 1998). A later study showed that MMP-9 knockout mice exposed to 
lysolecithin-induced demyelination showed a reduced capacity to recover (Larsen et al. 2003), 
demonstrating that MMP-9 may be beneficial in models that exhibit substantial white matter 
injury. These data clearly demonstrate the involvement of MMPs, and particularly MMP-9, in the 
ability of OLs to effectively differentiate and ultimately myelinate axonal tracts. Although MMP 
function regulates matrix turnover and is necessary during critical developmental stages, a 
multitude of studies have demonstrated that these enzymes contribute significantly to the 
neuropathies that result from ischemic insult. These data will be addressed in section IV. 
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Growth Factor Substrates for Matrix Metalloproteinases 
 Many additional MMP substrates have been identified in other experimental models. Data 
from these studies demonstrates the ability of MMPs to alter cell growth, signaling and migration 
(McCawley and Matrisian 2001). For example, MMPs have been shown to cleave ECM 
proteoglycans that are associated with growth factors, thus releasing these growth factors from 
sequestration. This has been demonstrated for fibroblast growth factor (FGF) in human 
endothelial cells after cleavage of the heparin sulfate proteoglycan perlecan (Whitelock et al. 
1996), as well as for transforming growth factor beta via decorin proteolysis (Imai et al. 1997). 
Similarly, MMP cleavage of non-matrix proteins such as insulin-like growth factor binding protein 
3 (IGFBP-3) can activate IGF in dermal fibroblast cultures (Fowlkes et al. 1994). Consistent with 
these data, blocking MMP activity with an endogenous inhibitor increased IGFBP-3 expression 
and reduced IGF-1 receptor signaling in a murine hepatic tumor model (Martin et al. 1999).  
Other evidence suggests that gelatinase MMPs can act on growth factor receptors to 
alter receptor turnover. In experiments that used a cervical carcinoma cell/mixed lymphocyte co-
culture system to study the effects of immunosuppression, MMP-9 was shown to cleave 
interleukin-2 receptor alpha on T-lymphocytes (Sheu et al. 2001). Additionally, MMP-2, but not 
MMP-9, cleaved FGFR1 from the cell surface, releasing a soluble form into the ECM that retained 
FGF-binding activity (Levi et al. 1996). Other known substrates for gelatinases include vascular 
endothelial growth factor and monocyte chemoattractant protein 3 (MCP-3), the cleavage of 
which could affect chemotaxis and thus alter the inflammatory response (Engsig et al. 2000; 
McQuibban et al. 2000).  
Although there is a paucity of data from in vivo ischemic models linking MMP activity to 
growth factors, the aforementioned studies illustrate the distinct ways in which MMPs modulate 
numerous cellular processes and may, in fact, provide protection depending upon the temporal 
activation profile and the overall conditions of the microenvironment. Elucidating the mechanisms 
by which these proteases contribute to perinatal H-I injury and identifying the substrates for which 
MMPs demonstrate high affinity in vivo may serve as crucial information when developing 
alternative therapeutic approaches to treat H-I injury in the future. 
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Endogenous Inhibitors of Metalloproteinases 
 The primary endogenous inhibitor of MMPs in the systemic circulation is αB2B-
macroglobulin. However, specialized tissue inhibitor of matrix metalloproteinase (TIMP) 
molecules regulate MMP activity in tissues and mediate ECM remodeling (Brew et al. 2000). As 
such, these proteins are important in regulating protease activity within the CNS. The TIMP family 
consists of 4 members. TIMP-1, -2 and -4 are soluble, secreted proteins. In contrast, TIMP-3 is a 
matrix-associated protein that is generally bound to ECM (Leco et al. 1994). Each TIMP contains 
an N-terminal and a C-terminal domain. The N-terminal domain confers inhibitory activity via a 
conserved cysteine residue that interacts with the zinc ion present within the MMP catalytic site. 
The C-terminal domain is variable among these proteins and therefore may reflect unique 
properties among the TIMPs. Inhibition results from a noncovalent bond that contacts both the 
catalytic and hemopexin domains of MMPs. The cell surface glycoprotein reversion-inducing 
cysteine-rich protein with kazal motifs (RECK) has also been shown to inhibit gelatinase MMPs 
(Oh et al. 2001; Takahashi et al. 1998). While RECK was shown to be involved in tumor 
metastisis, the role of RECK in the injured CNS is not clear. To date, many questions regarding 
the specific ways in which endogenous inhibitors regulate MMP function remain unanswered. 
Understanding the mechanisms in both the normal and injured brain may provide important 
insights into the molecular events leading to neural injury and potential therapeutic approaches to 
enhance neuroplasticity after injury.  
  
Cellular Responses to Hypoxia-Ischemia: 
The Early Response 
In the developing brain, H-I results in a biphasic injury profile. Many of the initial events 
leading to progressive damage have been identified. Perinatal rodents are particularly ketogenic 
due to the high fat content in rodent milk. In fact, ketones are a major energy source of the 
perinatal brain (Nehlig and Pereira de Vasconcelos 1993). In response to H-I, the immature brain 
relies heavily on anaerobic glycolysis and glucose utilization increases markedly (Vannucci et al. 
1994). The breakdown of glucose to lactic acid lowers pH, thus creating a more acidic 
 14
microenvironment. Anaerobic glycolysis is energetically unfavorable and results in rapid depletion 
of ATP, among other energy stores. Energy failure initiates a series of deleterious biochemical 
cascades. Free oxygen radicals produced from xanthine byproducts (resulting from breakdown of 
ATP) and prostaglandin synthesis (resulting from breakdown of free fatty acids) attack 
polyunsaturated fatty acids of the plasma membrane, increasing membrane permeability and 
ultimately leading to necrotic cell death. Endothelial cell death compromises the blood brain 
barrier, resulting in vasogenic edema and hemorrhage (Wetzel 2005). Although extravasation into 
the neuropil increases levels of interstitial glucose, the developing brain cannot efficiently utilize 
this energy source due to low levels of glucose transporters (Vannucci and Hagberg 2004). The 
failure of energy-dependent ion pumps causes cellular depolarization and the subsequent release 
of glutamate into the extracellular space. Glutamate, in turn, activates NMDA receptors, resulting 
in calcium influx. Excessive levels of intracellular calcium contribute to the production of free 
oxygen radicals and nitric oxide (NO), a potent molecule that activates lipid peroxidation by 
combining with superoxide to form peroxynitrite (Shalak and Perlman 2004). There is also 
evidence that NO activates MMP-9 (Gu et al. 2002). 
In addition to necrosis, apoptotic cell death occurs during the initial response to insult and 
may be the predominant mechanism accounting for cell death during the delayed response 
(Northington et al. 2001b). Mitochondrial dysfunction, in particular, is a major component of both 
the intrinsic and extrinsic apoptotic pathways. Either through death receptor activation (extrinsic) 
or some intracellular signal (intrinsic), the release of cytochrome c into the cytosol initiates the 
activation of caspases, proapoptotic cysteine proteases that induce programmed cell death upon 
activation. The perinatal brain expresses substantially high levels of several apoptotic proteins, 
including caspase-3 (Hu et al. 2000), APAF-1 (Ota et al. 2002), Bax (Vekrellis et al. 1997) and 
Bcl-2 (Merry et al. 1994). The expression of these proteins decreases throughout development, 
thus lending support to the notion that apoptosis may account for a significant proportion of cell 
death after ischemia. Indeed, previous studies have demonstrated increased activity of caspase-3 
(Blomgren et al. 2001) and caspase-9 (Zhu et al. 2003) after H-I, suggesting that the intrinsic 
pathway was activated. Other data showed increased expression of the Fas death receptor ligand 
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(FasL) in conjunction with activation of caspase-8 and caspase-3, indicating that the extrinsic 
pathway is also activated (Northington et al. 2001a) in response to insult.  
In the context of ECM interactions, these apoptotic pathways may be particularly 
important in initiating detachment-induced apoptotic cell death, termed “anoikis”. For example, 
pharmacological blockade of integrin signaling was shown to trigger anoikis, thereby reducing 
angiogenesis and inhibiting tumor progression (Brooks et al. 1994). Integrins are ECM 
components that mediate signaling in both the immature and the adult brain. As such, disruptions 
in integrin signaling after H-I may result in cell detachment from ECM and subsequent apoptotic 
cell death. To date, anoikis has not been adequately investigated in models of perinatal H-I. 
Despite this fact, several lines of evidence suggest that this mechanism may be largely 
responsible for cell death after ischemic insult. Anoikis has been documented after 
ischemia/reperfusion in the rat intestinal epithelium (Ikeda et al. 1998), indicating that ischemia 
does, in fact, trigger this mechanism. In experiments conducted with intestinal epithelial cells, the 
activation of several caspases that regulate both the intrinsic and extrinsic apoptotic pathways 
have been associated with anoikis (Grossmann et al. 2001) and mitochondrial dysfunction 
(Grossmann et al. 2001; Rytomaa et al. 2000). The increased expression of proapoptotic 
enzymes in the developing brain relative to the adult, coupled with the highly-regulated 
developmental expression profile of ECM lecticans and the high incidence of apoptotic cell death 
after H-I, demonstrate the need for future research into the potential involvement of ECM 
signaling in the context of apoptotic cell death after ischemia.  
 
Neuroinflammation: The Secondary Response 
The contributions of excitotoxicity and free radical production to the early ischemic 
response are clear. Despite this fact, selective targeting of these mechanisms has not led to 
significant functional improvements in clinical trials. Importantly, a second wave of cell death 
occurs in response to ischemic insult and is mediated by the neuroinflammatory response to 
injury. During this time, a myriad of proinflammatory molecules are released, initiating signaling 
cascades that ultimately exacerbate neural damage. Accumulating evidence suggests that 
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targeting neuroinflammatory mechanisms may be a promising avenue for therapeutic 
intervention.  
The immune response in brain is complex and highly regulated by a host of different cell 
types and signaling pathways. Resident microglia are among the first to become activated (Lai 
and Todd 2006). These cells migrate to necrotic regions where they remove cellular debris from 
the interstitial space. Also during this time, activated astrocytes upregulate glial fibrillary acidic 
protein (GFAP) and migrate to the injured site, a phenomenon known as reactive astrogliosis. 
Cells in and around the lesion core upregulate the expression of lecticans and these 
proteoglycans are deposited into the extracellular space. Thus, a dense composition of 
proteoglycans, reactive astrocytes and microglia invade the injured site and form a tissue barrier 
that is referred to as a “glial scar” (Silver and Miller 2004).The formation and progression of glial 
scarring is thought to be an innate protective mechanism in brain to isolate the injured area from 
viable surrounding tissue. As time progresses, however, the glial scar prevents neuroplasticity 
and repair at the lesion site while activated astrocytes and microglia promote further injury by 
secreting proinflammatory cytokines and chemokines, thus attracting peripheral macrophages 
(Chew et al. 2006). In concert, these immune cells and proinflammatory molecules contribute to a 
feed-forward inflammatory response by further enhancing microglia and macrophage recruitment 
to the injured site (Alvarez-Diaz et al. 2007). The end result is a heightened state of inflammation 
in the brain that promotes apoptotic cell death.  
Cytokines seated on cell surfaces are activated and subsequently released into the 
extracellular milieu, where they serve as important mediators of apoptotic cell death. Following 
ischemic insult, activated microglia upregulate the expression of various cytokines and 
chemokines (Fukui et al. 2006; Kim 1996; Van Lint and Libert 2007). In particular, tumor necrosis 
factor alpha (TNF-α) and interleukin-1 beta (IL-1β) have been shown to potentiate the 
neuroinflammatory response after H-I. There have been many investigations into the specific 
mechanisms by which cytokine activation enhances the inflammatory response in brain. 
Interleukin-1 type 1 receptor (IL-1R1) knockout mice showed significant reductions in the 
expression of macrophage inflammatory protein-1 alpha (MIP-1α), MIP-1β, MCP and RANTES 
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(Ur Uegulated upon UaUctivation, Un Uormal UTU cell Ue Uxpressed and UsUecreted) both 18 hrs and 72 hrs after H-
I compared to non-transgenic controls. These effects were also associated with reduced 
leukocyte infliltration (Lazovic et al. 2005), suggesting that IL-1β mediates chemotaxis of 
peripheral immune cells to the injured site. Other data from acute rat hippocampal slices showed 
that activation of alpha chemokine receptor 4 (CXCR4) by the natural ligand stromal cell-derived 
factor-1 (SDF-1) caused glutamate to be released from astrocytes. Interestingly, this response 
was found to be dependent on the release of TNF-α following CXCR4 activation, and was 
amplified in the presence of lipopolysaccharide (LPS)-stimulated microglia (Bezzi et al. 2001). 
These results lend further support to the notion that microglia contribute to unfavorable conditions 
after insult, working in concert with cytokines and chemokine activation. 
 
Matrix Metalloproteinases and Cerebral Ischemia: 
Blood Brain Barrier Degradation 
Following an ischemic event, activated glia contribute to the secondary inflammatory 
response by promoting glial scar formation and releasing proinflammatory molecules that further 
recruit immune cells to the injured site. Although the precise mechanisms by which these effects 
are achieved have yet to be determined, data from numerous studies suggests that MMPs are 
instrumental in the production and maintenance of a proinflammatory microenvironment 
(Manicone and McGuire, 2008). The release of proteases from activated microglia results in 
proteolytic degradation of basement membrane constituents (del Zoppo et al. 2007). This 
breakdown compromises the blood brain barrier, causing extravasation that permits entry of 
peripheral leukocytes and macrophages into the brain. Gelatinases, in particular, are major 
contributors to ischemic pathology (Wetzel 2005). In vivo experiments revealed MMP-9 
expression that was localized to neutrophils and endothelial cells, and showed elevated MMP-2 
expression in astrocytic endfeet (Rosenberg et al. 2001). The latter expression profile places 
MMP-2 in the ideal position to proteolytically process basement membrane proteins, as astrocytic 
endfeet play an important role in sealing the blood brain barrier. An elegant study later supported 
this mechanism by showing that laminin is a key substrate for MMPs after ischemia. Gelatinase 
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activity increased in cortex after MCA occlusion, and active MMP-9 was upregulated and 
proteolytically processed laminin when incubated with tissue homogenates from ischemic brain. 
These effects were attenuated after administration of a highly selective gelatinase inhibitor (Gu et 
al. 2005). There is now substantial data demonstrating the degradation of basement membrane 
proteins by several MMPs that are elevated after ischemia (Cunningham et al. 2005; Manicone 
and McGuire 2008; Rosenberg and Yang 2007).  
 
Sheddase Activity and Extracellular Matrix Remodeling 
There is accumulating evidence suggesting that gelatinases may contribute to the 
inflammatory response through “sheddase” activity, the process by which MMPs cleave 
proinflammatory cytokines attached to cell surfaces. This proteolytic processing, in turn, activates 
and releases these molecules into the extracellular milieu to exert a wide range of effects 
depending upon the specific state of the microenvironment. MMPs have previously been shown 
to process both TNF-α (Gearing et al. 1994) and IL-1β (Schonbeck et al. 1998) to their 
biologically active forms. In culture, MMP-2 – positive astrocytes produced MMP-9 when 
stimulated with either TNF-α or IL-1β (Gottschall and Yu 1995).  In agreement with these data, 
mice lacking MMP-9 showed improved outcomes that were directly related to reduced microglial 
activation (Svedin et al. 2007), attenuated blood brain barrier degradation (Gidday et al. 2005) 
and limited white matter damage (Asahi et al. 2001). Other data showed that gelatinases cleaved 
SDF-1α and various MCP chemokines (Overall et al. 2002), and SDF-1 accelerated proteolytic 
processing of syndecans by MMP-9 (Brule et al. 2006). Cerebral blood vessels express high 
levels of syndecans, which modulate transendothelial migration of monocytes across the brain 
endothelium (Floris et al. 2003). Taken together, these data offer potential mechanisms by which 
gelatinase activity enhances neuroinflammation after H-I by facilitating immune cell chemotaxis. 
In addition to their roles in activating cytokines and processing basement membrane 
proteins, MMPs are efficient at cleaving lecticans (Gottschall 2005). Lecticans are upregulated in 
glial scars, where their growth-inhibitory properties act as a barrier between injured and viable 
tissue (Sandvig et al. 2004; Silver and Miller 2004). Thus, lectican proteolysis by MMPs may have 
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profound effects on perinatal brain plasticity after injury. Both full-length brevican and the G1 
proteolytic fragment were reduced 1 and 14 days after insult in hippocampi of neonatal rats that 
were exposed to H-I (Aya-ay et al. 2005). While the mechanisms of this loss were unclear, the 
temporal association of brevican loss with lesion progression suggests that brevican expression 
may be critical for cell viability in the developing brain. In this context, brevican loss resulting from 
either proteolytic cleavage or cellular injury may enhance neural cell death. Though MMPs are 
upregulated in glial scar after spinal cord transection (Duchossoy et al. 2001), very little is known 
regarding the specific effects of MMPs on glial scar formation and ECM proteolysis after neonatal 
H-I. Potential mechanisms may include the induction of cellular anoikis or the facilitation of 
microglia and macrophage migration via reduced steric hindrance resulting from increased ECM 
clearance.    
 
Extracellular Matrix, Matrix Metalloproteinases and Hypoxic- 
 
Ischemic Injury: The Big Picture 
 
To date, the majority of research into neonatal H-I has emphasized the contributions of 
glutamate excitotoxicity and free radical production to the resulting neuropathology (Shalak and 
Perlman 2004). Consistent with evidence supporting the roles of free radical production and 
oxidative stress (Back et al. 1998; Elibol et al. 2001; Ferriero et al. 1996; Jian Liu and Rosenberg 
2005), therapeutic approaches targeting these mechanisms in rodents have been of some benefit 
(Arvin et al. 2002; Follett et al. 2000). Nonetheless, most studies showing improved outcomes 
have limited clinical relevance, as protective agents were administered prior to or shortly after 
insult. Thus, the search continues for more selective therapeutics that do not interfere with critical 
cellular functions (Hamrick and Ferriero 2003) and can be administered at clinically relevant time 
points. The intent of the current study was to characterize the injury profile in rat using the 
Vannuci model of neonatal H-I, to determine whether ECM lecticans and/or matrix-degrading 
proteases contribute to the maladaptive responses to insult, and to test whether the selective 
targeting of gelatin-degrading MMPs provides neuroprotection at a delayed time point.  
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Lecticans are ubiquitous ECM substrates that influence axonal targeting, providing 
signals to neighboring cells and structural stability throughout the extracellular milieu (Yamaguchi 
2000). Lectican expression is highly regulated in developing rodents. Interestingly, increased 
expression is associated both temporally and spatially with OL differentiation from pre-OLs to 
mature, myelinating cells. Additionally, data from rodent models indicates that lecticans serve as 
inhibitory substrates to neuroplasticity in the injured brain (Asher et al. 2000; Jaworski et al. 
1999). Despite these data, little is known regarding the mechanisms by which lecticans may 
contribute to white matter dysfunction or glial scar formation after H-I. Preliminary data from our 
laboratory showed that the lesion resulting from H-I is progressive in the rat neonate. It is also 
noteworthy that pre-OLs show selective vulnerability to H-I injury in the Vannucci model (Back et 
al. 2002; Craig et al. 2003; Skoff et al. 2001), similar to the clinical population. Upon considering 
the expression profile of lecticans in developing white matter, as well as their contribution to the 
formation and maintenance of the glial scar in other injury models, the first set of experiments 
were designed to test the following hypotheses: 1) the death of pre-OLs after H-I is 
associated with reduced lectican expression, and 2) increased lectican deposition is 
associated with lesion progression and glial scarring.  
In addition to cleaving lecticans, matrix-degrading proteases (particularly MMPs) 
proteolytically process various ECM substrates and demonstrate “sheddase” activity on cell-
surface proteins. MMP-9 knockout mice showed improved outcomes after cerebral ischemia 
induced using either the Vannucci model that mimics neonatal H-I (Lee et al. 2004; Svedin et al. 
2007) or the MCAO model that mimics adult stroke (Asahi et al. 2000; Asahi et al. 2001; Gidday 
et al. 2005). While accumulating evidence indicates that gelatin-degrading MMPs mediate the 
neuroinflammatory response to injury, little is known regarding the specific mechanisms by which 
these proteases may contribute to H-I injury in the developing rat brain.  
A couple of points are worthy of mention. Minocycline has been shown to exert 
neuroprotective effects in several rat injury models (Cai et al. 2006; Fan et al. 2006; Yao et al. 
2001). This compound is a tetracycline derivative with anti-inflammatory properties that are 
achieved primarily by the chelation of calcium ions. However, minocycline chelates other divalent 
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cations as well and has previously been shown to exert MMP inhibition both in vitro and in vivo 
(Machado et al. 2006), most likely through chelation of the zinc ion that is present within the 
catalytic site of MMPs. In contrast, AG3340 (prinomostat), a small molecule hydroxamate-based 
inhibitor of MMPs, is a potent MMP inhibitor with high nanomolar affinity for gelatinases. Both 
minocycline and AG3340 are orally bioavailable and therefore are attractive therapeutic agents 
for clinical use. AG3340 has been tested in various experimental cancer models and has 
demonstrated efficacy in limiting tumor growth in rodents (Alves et al. 2001; Price et al. 1999). To 
date, the efficacy of AG3340 in reducing neural injury has not been tested in the neonatal H-I 
model. However, data from previous experiments lend support to the notion that selective 
targeting of MMP-2 and MMP-9 could improve the outcome. The effects of gelatinase inhibition 
were examined in a model of chronic cerebral hypoperfusion. Data revealed that AG3340 
provided neuroprotection in adult rats and mice when administered just prior to insult. Importantly, 
reduced activation of astrocytes and microglia was associated with retained blood brain barrier 
integrity (Nakaji et al. 2006). In a mouse model of MCAO, the gelatinase-selective compound SB-
3CT reduced infarct volume when administered either 2 or 6 hrs, but not 10 hrs, after insult (Gu et 
al. 2005).  
Due to the distinct mechanisms of action between minocycline and AG3340, a direct 
comparison of the efficacy of these compounds within a single study would provide information as 
to the relative contributions of generalized anti-inflammatory actions and MMP inhibition, 
specifically. Furthermore, treatment at a delayed time point would extend the clinical relevance if 
neuroprotection is, in fact, achieved. Therefore, the second series of experiments were 
designed to test the following hypotheses: 1) Treatment with minocycline or the selective 
gelatinase inhibitor AG3340 will provide neuroprotection when administered at a delayed 
time point, 2) neuroprotection will be associated with reduced neuroinflammation, and 3) 
minocycline will demonstrate greater efficacy in providing neuroprotection and reducing 
neuroinflammation when compared to AG3340.  
Resident microglia are among the first cells activated in response to cerebral ischemia 
(Lai and Todd 2006). In the developing brain, these immune cells mediate the neuroinflammatory 
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response through a variety of mechanisms (Chew et al. 2006). In the case of ischemia, activated 
microglia upregulate the expression of cytokines and chemokines, enhancing the inflammatory 
response (Fukui et al. 2006; Kim 1996; Van Lint and Libert 2007). Increased expression of 
MMPs, particularly gelatinases, occurs concomitantly. Another known mechanism by which 
gelatinase activity exacerbates injury is through proteolytic processing of blood brain barrier 
constituents (del Zoppo et al. 2007; Rosenberg et al. 2001). In this instance, extravasation 
resulting from blood brain barrier degradation permits entry of monocytes/macrophages into the 
brain, further enhancing the recruitment of immune cells to the lesion site (Alvarez-Diaz et al. 
2007). Infiltrating leukocytes (Gidday et al. 2005) are also sources of MMPs, though there is 
some evidence that microglia are the primary macrophages that respond to neonatal ischemic 
injury (Denker et al. 2007). Nonetheless, the relative contributions of the resident and peripheral 
immune responses to neonatal H-I injury have not been elucidated.  
To investigate this further, organotypic slice culture methodology would be advantageous 
in that it allows for mechanistic experimentation in the absence of peripheral immune cell effects, 
while more closely mimicking the microenvironment in brain when compared to other cell culture 
systems. Thus, slices could be incubated with known concentrations of the appropriate 
compounds that correspond to the in vivo concentrations achieved after dosing in the animal. 
Additionally, gelatinase activity could be measured in all treatment conditions to further assess 
the degree to which gelatinase activity was associated with cell death. Together, these data 
would provide insight into the relative contributions of anti-inflammatory and MMP-inhibitory 
effects on cell survival. Therefore, the final series of experiments were designed to test the 
following hypotheses: 1) Oxygen glucose deprivation will increase gelatinase activity and 
neurodegeneration, 2) treatment with either minocycline or AG3340 will reduce gelatinase 
activity and neurodegeneration in slices exposed to OGD, and 3) AG3340 and minocycline 
will demonstrate equal efficacy in providing neuroprotection in slices exposed to OGD. 
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UAbstract 
The developing brain is uniquely susceptible to injury after exposure to hypoxia-ischemia 
(H-I). Lecticans are developmentally regulated in formative white matter and exert growth-
inhibitory effects in several adult injury models, yet little is known regarding their role in neonatal 
H-I injury. The main objectives of this study were to examine the expression profiles of brevican 
and versican in rat using a standard H-I model, and to determine whether altered expression was 
associated with distinct components of white and gray matter pathology. The H-I procedure 
produced progressive injury limited to ipsilateral hemisphere. Cresyl violet staining revealed 
severe cavitary infarctions at 14 and 21 days that were absent at 4 days. Cellular damage, as 
measured by GFAP and fractin immunoreactivity, occurred in cortical and subcortical gray matter 
at all endpoints. O4 sulfatide immunoreactivity was reduced in white matter of external capsule, 
hippocampal fimbria and corpus striatum at 4 days relative to contralateral, suggesting the loss of 
pre-oligodendrocytes. Brevican expression was reduced in cortex and hippocampus at 4 days but 
was markedly elevated at later endpoints, localizing to regions of cellular damage both within and 
proximal to the lesion core. Versican deposition was increased most prominently at late endpoints 
in cortex of moderately lesioned tissue. In contrast, versican was reduced in external capsule 4 
days after H-I, a reduction that was sustained at 21 days. These data demonstrate unique 
expression profiles for lecticans after neonatal H-I, suggesting brevican deposition is elevated in 
response to progressive gray matter injury while diminished versican expression may be 
associated with deep cerebral white matter injury. 
 
UKeywords:U chondroitin sulfate proteoglycans; hypoxia-ischemia; oligodendrocytes; rat; 
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UIntroductionU 
The developing brain is uniquely susceptible to injury after exposure to a hypoxic-
ischemic (H-I) environment (Volpe 2001). Such insults produce a neural sequelae characterized 
by cortical and periventricular white matter injury (PWMI) (Rezaie and Dean 2002). Current views 
regarding mechanisms of PWMI emphasize perturbations of normal developmental myelination, 
while gray matter damage is associated with a multitude of factors that aid in the formation and 
progression of a dense composition of proteoglycans, reactive astrocytes and glia that constitute 
a glial scar (Silver and Miller 2004). An important clinical study revealed that oligodendrocyte 
precursor (pre-OL) proliferation and differentiation are coincident with the developmental period 
(23-32 gestational weeks) during which pre-term infants are most vulnerable to H-I injury (Back et 
al. 2001). Since that time, a growing body of literature has emerged indicating  that white matter 
pathology observed in response to H-I is directly related to the selective vulnerability of pre-OLs, 
resulting in lower numbers of mature OLs and compromised myelination in the adult (Back et al. 
2002; Craig et al. 2003; Skoff et al. 2001).  
To date, the majority of research has emphasized excitotoxicity, reactive oxygen species 
and inflammation as key contributors to both white and gray matter injury (Shalak and Perlman 
2004). While there is strong and convincing evidence supporting the roles of oxidative stress and 
free radicals (Back et al. 1998; Elibol et al. 2001; Ferriero et al. 1996; Jian Liu and Rosenberg 
2005), clearly other mechanisms are involved, and while therapeutic approaches targeting these 
cascades have been of some benefit in animal models (Arvin et al. 2002; Follett et al. 2000), the 
search continues for therapeutic interventions that do not interfere with normal maturational 
processes (Hamrick and Ferriero 2003). One potential avenue for novel therapeutic intervention 
may involve selective targeting of lecticans. Glia contained within developing white matter tracts 
are surrounded by lecticans, a sub-family of chondroitin sulfate-bearing proteoglycans (CSPGs) 
that include brevican, versican, aggrecan and neurocan. Lecticans constitute the preponderance 
of extracellular matrix (ECM) in the brain, exerting effects on cellular adhesion, signaling and 
neurite outgrowth (Yamaguchi 2000). Lectican expression is highly regulated in developing 
rodents. The PGs are deposited by pre-OLs during the transition period from immature to mature, 
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myelinating OLs, suggesting a role in this transition process, while deposition subsequent to the 
active myelination period occurs mainly via astrocytes (Asher et al. 2002; Ogawa et al. 2001). 
The capacity of lecticans to act as non-permissive substrates to tissue remodeling has also been 
documented in certain injury models (Asher et al. 2000; Jaworski et al. 1999). Despite these data, 
little is known regarding the mechanisms by which lecticans may contribute to white matter 
dysfunction or glial scar formation after H-I.  
The most common experimental animal model currently used to recapitulate human 
neonatal H-I was originally developed by Levine (Levine 1960) and reprised by Vannucci and 
colleagues for use in the neonate (Rice et al. 1981). The pathology in this model mimics that 
observed in human neonatal brain injury, including ventricular dilation and deep cerebral white 
matter injury, while retaining the gray matter component that is observed in various animal 
models of injury.  Lectican expression is developmentally regulated in white matter and up-
regulated in glial scar tissue, suggesting that lecticans may play a supporting role in normal white 
matter development while impeding reparative processes in injury states. However, little is known 
regarding the pattern and location of lectican deposition in relation to the pre-OL. Therefore, the 
present study was conducted to investigate the spatio-temporal relationship of lectican deposition 
in the rat neonate after exposure to H-I, and to determine the association of brevican and 
versican with both white and gray matter pathology.   
 
UMaterials and Methods 
Induction of Hypoxia-Ischemia 
All animal procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals. Neonatal Sprague-Dawley rats were birthed from time-pregnant 
dams (Harlan Labs). Rats were maintained on a 12 hour light/dark cycle (7 am – 7 pm) and given 
access to food and water ad libitum. Two separate litters from 2 dams were culled to 10 pups per 
litter at P1 and cross-fostered randomly between dams prior to each experiment. Animals 
included in this study were pooled from 2 experiments. The H-I procedure was performed at P7 
and consisted of permanent unilateral ligation of the common carotid artery followed by transient 
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exposure to hypoxia. All animals were placed on a heating pad (37°C) during surgery to minimize 
variation that results from differences in core body temperature. Animals were initially 
anesthetized with 2.5% isofluorane and subsequently maintained at 350 ml/ml of oxygen and 
1.5% isofluorane with an interfaced scavenging system for the duration of the surgery. The right 
common carotid artery was isolated away from the vagus nerve with blunt dissection and 
permanent ischemia was achieved by ligating the carotid artery with 6 x 0 nylon suture. The 
musculature and skin were then sutured and animals were placed back with their corresponding 
dams for 2 h. After the recovery period, pups were exposed to 8% oxygen/N B2 BbalancedB Bfor 120 
minutes. During hypoxia, pups were placed into custom-made chambers that maintained a 
temperature of 37˚C while permitting a water-saturated oxygen mixture to be dispensed at a 
constant flow rate (Aya-ay et al. 2005). Since physiological parameters were not monitored during 
the hypoxic period, naïve (no ligation, no hypoxia) and sham (permanent ligation, no hypoxia) 
animals were included for direct comparisons with H-I littermates within each experiment.  Pups 
were then returned to their respective dams and body temperature was maintained at 37˚C for 2 
h with a heating pad prior to the conclusion of the experiment.  
  
Perfusion and Tissue Preparation 
For immunohistochemistry, tissue was collected at 4 (P11), 14 (P21) and 21 days (P28) 
after H-I as previously described (Aya-ay et al. 2005), with minor adaptations. Briefly, animals 
were anesthetized with pentobarbital (60 mg/kg) and intracardially perfused with 60 ml 
phosphate-buffered saline (PBS, pH 7.4) followed by 60 ml 4% paraformaldehyde. Brains were 
removed and cryopreserved with increasing sucrose concentrations (15%, 30%), sectioned 
coronally on a cryostat at 30 µm thickness and thaw-mounted onto slides for cresyl violet staining 
or immunohistochemistry. Thaw-mounting was chosen over free-floating sections to achieve 
maximum preservation of morphology in tissue proximal to lesion. Every third section was 
collected from an area contained within the lesion that ranged from the most rostral aspect of the 
lateral ventricles to the initial emergence of brainstem.   
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Histology and Immunohistochemistry 
Cresyl violet-stained brain sections were used for verification and quantification of gross 
lesion areas. Sections were rinsed briefly in PBS, dried overnight and baked for 60 minutes at 
50˚C. Sections were then rehydrated in decreasing concentrations of ethanol (100%, 95%, 70 %), 
stained with cresyl violet solution (3%) for 3 minutes, dehydrated (70%, 95%, 100%), cleared with 
Histoclear and mounted in Permount. Immunohistochemistry  was performed as described 
(Mayer et al. 2005)  to assess cellular damage, lectican expression and relative abundance of 
pre-OLs. All data was obtained from 5 distinct regions in brain (figure 1) collected at P11 (N=6), 
P21 (N=5) and P28 (N=7).  Briefly, slides were rinsed with PBS, permeabilized and blocked for 60 
minutes (3% Triton-X, 3% 1M Lysine, 10% NGS in PBS) and incubated overnight with primary 
antibody. Sections were then rinsed, incubated with secondary antibody and coverslipped using 
Vectashield aqueous mounting media (Vector Labs, Burlingame, CA). Double-label 
immunohistochemistry was achieved by co-incubation with anti-mouse and anti-rabbit primary 
antibodies, and subsequent co-incubation with secondary antibodies conjugated to distinct 
fluorophores for each respective species of primary antibody.  
Primary antibodies used in these studies were mouse anti-glial fibrillary acidic protein 
(GFAP, Boeringher-Manheim, 1:1000), rabbit anti-fractin (Chemicon, 1:1000), rabbit anti-brevican 
(BD Transduction Labs, 1:500), mouse anti-12C5 (Developmental Hybridoma Bank, 1:500), rabbit 
anti-NG2 (Chemicon, 1:1000) and mouse anti-O4 sulfatide (Chemicon, 1:1000). Primary 
antibodies were visualized using either Alexa Fluor 488 (green) or Alexa Fluor 594 (red) 
secondary antibodies (Molecular Probes, Eugene, OR).  
 
O4 Sulfatide Quantification 
O4 sulfatide was quantified using ImageJ software. All images were captured at the same 
exposure time on a single day to eliminate confounds of differential background intensity and 
diminished fluorescence intensity over time. Low power photomicrographs of adjacent tissue 
sections (2 sections per animal) from P11 rats (N=6) corresponding to approximately Bregma 
0.70 mm (Paxinos and Watson) were imported into ImageJ and converted to 8 bit binary images. 
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External capsule (EC) was traced and background subtraction was achieved by adjusting 
contrast until background particles were eliminated from the selected regions. Analyses yielded 3 
distinct measures that included total area of external capsule (“EC area”), total number of 
particles within the traced area (“O4 intensity”) and the proportion derived from dividing the total 
particle area by the total area of the selected region (“area fraction”). 
  
Statistical Analyses 
 For quantification of external capsule white matter loss, data were expressed as X ± SEM 
of proportions derived from values obtained ipsilateral divided by contralateral within each animal. 
These data were subjected to one sample student’s t-tests using the null hypothesis that the 
mean of the ipsilateral to contralateral side proportion was equal to 1.0. When p< 0.02, deviation 
from the null hypothesis was considered significant.  This "p value" was chosen, rather than p < 
0.05, to account for potential type I errors that would occur due to conducting multiple t-tests.  
 Data from lesion area quantification were obtained as described above and converted to 
percentages, representing percent  ipislateral relative to contralateral for each animal. Group 
values were then subjected to a one-way ANOVA with “p value” set at 0.05. Pair-wise comparison 
of group means was made using a Tukey post-hoc test. 
 
UResultsU 
Progressive Lesion after H-I 
Neonates were subjected to H-I at P7 and sacrificed 4 (P11), 14 (P21) and 21 (P28) days 
after insult. Brain sections were collected and stained with cresyl violet to determine the extent of 
lesion. This model resulted in lesions of variable severity but demonstrated a clear profile 
whereby the extent of lesion increased as a function of time from P11 to the later endpoints 
(Figure 2). Data revealed significant increases in lesion area at P21 in all areas measured relative 
to P11 (p<0.05). While a clear trend for an increase was observed at P28, variability within the 
model (eg non-lesioned animals) prevented the mean from reaching statistical significance. 
However, when 3 animals from P28 whose values were similar to unlesioned animals (and 
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potentially never lesioned) were removed from the analysis, the P28 means reach significance in 
each region measured.  Animals sacrificed at P11 typically displayed ipsilateral hemispheric 
shrinkage accompanied by ventricular dilation. In general, the total area encompassing each 
region selected for analysis was slightly reduced. Cortical cavitations were present in some cases 
but severe cavitations of hippocampus and cortex were rarely observed. In contrast, nearly all 
lesioned animals sacrificed at later endpoints exhibited severe cavitary infarctions throughout the 
cortex and complete or near complete elimination of hippocampal structure. This more severe 
lesion profile was nearly identical at P21 and P28, indicating that the gray matter component is 
progressive and probably reaches a maximum threshold, at least for grossly observable 
infarction, 14 days or less after the insult. While elimination of white matter was observed in 
regions of external capsule adjacent to severe cortical infarctions, sections from animals with only 
mild to moderate cavitations largely retained the structure. Taken together, these data suggest 
that the neurohistological outcome in this model is most closely associated with gray matter 
injury. 
 
Reactive Gliosis and Apoptosis in Gray Matter 
Cresyl violet staining revealed a progressive lesion profile. Immunohistochemistry was 
performed on H-I tissues to identify early and late cellular damage profiles (Figure 3). The glial 
scar that is characteristic of gray matter injury is known to be composed largely of reactive 
astrocytes and glia. Indeed, animals sacrificed at P11 demonstrated clear elevations in GFAP 
immunoreactive positive cells in the ipsilateral hemisphere. The most prominent increases were 
found to be localized to cortical, hippocampal and striatal regions, while only modest increases 
were observed in white matter of external capsule and hippocampal fimbria. Intense GFAP 
immunoreactivity was observed at P21 and P28 in cortex, exhibiting the ‘columnar’ pattern typical 
of this model, in corpus striatum and remaining hippocampal structure. The extent and intensity of 
labeling was clearly increased several-fold at later endpoints relative to P11. In addition to 
reactive gliosis, we also sought to determine the degree to which apoptosis contributes to the 
early phase of injury. Double-label immunohistochemistry was performed in the same P11 
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sections probing for the apoptotic marker fractin, a neoepitope of β-actin that is generated upon 
cleavage by caspases 3 and 5. Intense fractin immunoreactivity was observed in the ipsilateral 
cortex at P11 and was consistent with the anatomical location of severe infarctions that were 
observed at P21 and P28. Fractin labeling was also found in the CA3 region of hippocampus but 
was absent in deep cerebral white matter. These findings suggest that the gray matter lesions 
produced in this model occurred, at least in part, as a result of caspase-mediated apoptotic cell 
death. Interestingly, fractin labeling was conspicuously low  or absent in white matter. Our inability 
to detect fractin in white matter may have been due to lack of sensitivity and/or differences in 
overall expression of β-actin throughout the brain. 
 
Brevican Deposition is Associated with Lesion Progression in Gray Matter  
Because glial scars have been previously shown to be rich in proteoglycans in several 
rodent injury models, we sought to characterize the expression of brevican and versican in this 
model of neonatal H-I. Sections obtained from P11, P21 and P28 animals that underwent H-I and 
demonstrated grossly observable infarctions and/or elevated cellular damage markers were first 
probed for brevican (Figure 4). Brevican immunoreactivity was reduced in the ipsilateral 
hemisphere 4 days after H-I. The greatest reductions were observed in hippocampus, where 
brevican was clearly reduced throughout the structure and most prominently in dentate gyrus. 
Cortical regions also exhibited reductions in brevican labeling overall, though we did detect 
sparsely distributed punctate staining in some sections. To determine whether the regions that 
exhibited reductions in brevican were also those regions affected by the insult, the same sections 
were probed for fractin. The results showed complete overlap between intense fractin 
immunoreactivity and the absence of brevican immunoreactivity, demonstrating that diminished 
brevican was coincident with elevated fractin and therefore suggesting that reduced brevican 
expression is associated with cellular apoptosis in the early phase of lesion progression.  
Analyses of later endpoints revealed that the expression profile for brevican was the 
opposite of that observed 4 days after insult. Sections collected from animals at P21 and P28 
demonstrated increased brevican immunoreactivity in cortical regions that were anatomically 
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consistent with gray matter damage. That is, brevican was elevated in those columnar regions 
where GFAP and fractin showed intense immunoreactivity (Figures 3 and 4). Because the lesions 
had progressed to severe cavitary infarctions by P21 and P28, very little hippocampus remained 
in the majority of tissues that were probed for brevican and therefore it was not possible to make 
direct comparisons relative to contralateral. We were occasionally able to visualize fragments of 
shrunken hippocampus, however, and in each of these cases brevican labeling was observed in 
the form of a thick border surrounding the structure. These results demonstrated an increase in 
brevican expression concomitant with a progression in lesion severity between 4 and 14 days 
after H-I. Upon comparison of P21 and P28 animals, we detected no differences in local 
expression or intensity of brevican labeling (not shown), indicating that the time course for peak 
brevican expression is similar to that of lesion progression from cellular damage, in the absence 
of cavitation, to severe cavitary infarction. Taken together, these data support the notion that 
increased brevican expression is associated with the progression of gray matter pathology.  
 
Versican is Differentially Expressed in Gray and White Matter 
 Although versican has also been implicated in glial scar formation, little is known 
regarding the role of versican in neonatal H-I pathology. Therefore, we examined versican 
expression in sections from P11, P21 and P28 lesioned animals (figure 5). The expression 
pattern for versican was found to be similar, but not identical, to that of brevican. At P11, versican 
immunoreactivity was moderately reduced in ipsilateral hippocampus and striatum in the majority 
of sections analyzed, though these reductions were of a lesser magnitude when compared to P11 
brevican. In contrast, no differences in cortical versican expression were detected at the early 
endpoint. In fact, cortical versican immunoreactivity was quite low 4 days after H-I and only in rare 
instances did we observe diffuse, punctate labeling. Analyses of later endpoints revealed 
elevations in cortical versican expression similar to those observed for brevican, with the 
exception that versican immunoreactivity, while elevated relative to control hemisphere at both 
late endpoints, was greatest in moderate lesions. We detected no differences in hippocampus at 
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P21 and P28. Although some remaining hippocampal structures exhibited the border-labeling 
similar to that observed with brevican, the intensity was low and inconsistent across sections.   
 The most interesting finding from these studies arose upon inspection of white matter. 
While we were unable to detect changes in white matter brevican expression, the developmental 
expression of versican clearly increased from P11 to P21 on the non-lesioned side. Versican 
immunoreactivity was detected in the contralateral external capsule and hippocampal fimbria of 
both hemispheres 4 days after H-I, but clear reductions were observed in ipsilateral external 
capsule (Figure 5). Closer inspection revealed that versican was diminished in lateral regions of 
external capsule that were seated ventral-medial from cortical regions of intense GFAP and 
fractin labeling. Smaller differences were found in medial regions of external capsule. Analyses of 
later endpoints revealed marked reductions in versican expression in ipsilateral external capsule. 
By P21, a developmental increase resulted in intense versican immunoreactivity in contralateral 
external capsule that was strikingly lower in the ipsilateral hemisphere (Figure 5). These data 
indicate that the basal increase in versican expression from P11 to P21 was diminished in the 
ipsilateral hemisphere following an H-I insult, suggesting that the perturbation of developing white 
matter that occurs after H-I may be linked to versican expression. 
 
White Matter Loss after Hypoxia-Ischemia 
 
White matter injury in response to H-I has been linked to selective vulnerability of pre-
OLs. Animals were sacrificed 4 days after H-I (P11) and sections were probed for the putative 
pre-OL marker O4 sulfatide (Figure 6). Intense O4 labeling was detected in the contralateral 
hemisphere throughout external capsule, hippocampal fimbria and the white matter-containing 
fiber tracts of corpus striatum. Consistent reductions occurred ipsilateral in each selected region 
relative to the corresponding contralateral region. In general, the magnitude and intensity of O4 
labeling was reduced in both corpus striatum and external capsule. While a reduction in the 
number of fiber bundles in the lateral portion of corpus striatum was evident, the relative 
proportions in the medial aspects of the structure were variable and inconsistent across animals. 
O4+ immunoreactivity was clearly reduced in external capsule after H-I and this effect, similar to 
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that observed in corpus striatum, was most prominent in lateral portions of the structure. To 
determine the degree of deep cerebral white matter loss, O4+ immunoreactivity was quantified in 
external capsule using 3 distinct measurements (Figure 7). The use of multiple measurements 
provided us with internal validation of our method as well as additional descriptive data. The 
results revealed significant reductions in all measures, including total area of external capsule 
(total area = 37 +/- 8%), O4+ immunoreactivity count (O4 intensity = 25 +/- 8%) and relative 
proportion of the total area that labeled O4+ (area Fraction = 31 +/- 7%). 
 
UDiscussionU 
Current rodent H-I models that mimic human PWMI also display substantial cortical and 
subcortical gray matter pathology (Towfighi et al. 1995; Vannucci et al. 1999). Several 
mechanisms have been proposed to account for H-I injury, including excitotoxicity, free radical 
production, inflammation and glial scar formation (Ashwal and Pearce 2001). The role of lecticans 
as inhibitory substrates to neural plasticity and tissue remodeling is well documented both 
throughout normal development and in several models of brain injury (for review see (Galtrey and 
Fawcett 2007). By virtue of their discreet, developmental expression and their key role in neural 
plasticity, lecticans are prime candidates for contributing to glial scar formation and white matter 
injury. Brevican and versican are lecticans that share common features in that they are present in 
high abundance in brain and are secreted by glial cell types under developmental regulation. The 
role of these molecules in response to H-I, however, has not been extensively investigated. Our 
objective was to characterize the expression of brevican and versican at selected endpoints that 
included both early and late phases of injury, and to determine the association of these lecticans 
with distinct H-I pathology. Data revealed a progressive lesion profile from the early to later 
endpoints. Animals sacrificed 14 or 21 days after insult developed severe cortical and subcortical 
cavitary infarctions that were less obvious 4 days after H-I. Ipsilateral elevations in fractin and 
GFAP immunoreactivity support the notion that reactive astrogliosis and apoptosis may contribute 
to neuronal cell death in cortex and hippocampus, in particular. A small proportion of animals 
exposed to H-I did not develop lesions. Therefore, the assessments of cellular damage markers 
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served two purposes in that we were able to detect pathology at the cellular level, in the absence 
of grossly observable infarctions, as well as select only those tissues that exhibited H-I pathology 
for subsequent examination of lectican expression profiles and white matter injury.   
Several studies have demonstrated elevations in CSPGs in response to injury (Beggah et 
al. 2005; Jones et al. 2003a; Jones et al. 2003b; Mayer et al. 2005; Vorisek et al. 2002). In 
general, these molecules are known to inhibit neurite outgrowth and therefore might be expected 
to act as non-permissive substrates to tissue repair in this model as well (Morgenstern et al. 
2002). Here we report that two members of the lectican family of CSPGs respond differentially to 
H-I, and appear to be associated with distinct components of the resulting pathology. Increased 
brevican expression has been reported in cortex after a cortical stab wound (Jaworski et al. 
1999), data consistent with our results. With the exception of the early endpoint where brevican 
was reduced in cortex, intense cortical brevican immunoreactivity was evident by P21. The 
reduction in the early phase of injury confirms data previously published by our laboratory (Aya-ay 
et al. 2005). Severe cavitary infarctions at later endpoints prevented any direct comparisons 
between contralateral and ipsilateral hippocampi. However, we were able to detect brevican that 
was deposited in thick borders surrounding the remaining ipsilateral hippocampal structures, 
indicating that brevican was being secreted at the perimeter of the infarctions and therefore was 
likely contributing to the production of an inhibitory microenvironment. The fact that brevican was 
reduced at P11 but elevated at later endpoints, a profile that occurred in conjunction with 
increased astrogliosis, provides evidence that increased expression and/or deposition of brevican 
may aid in glial scar formation resulting from extensive gray matter injury.  
The pattern of versican expression after H-I was somewhat unpredicted, differed from 
that of brevican, and suggests a dual role for versican in H-I pathology. Only modest changes in 
expression were detected in gray matter at P11 and were limited to hippocampus. Versican was 
previously shown to be upregulated in cerebral cortex of adult rats 7 days after unilateral knife 
lesion (Asher et al. 2002). The fact that we observed no changes in cortical versican 4 days after 
H-I may be due to differences in the experimental models or detection methodologies employed. 
One likely possibility is that limitations in plasticity that are characteristic of adult rodents may 
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result in an accelerated response profile when compared to younger animals which display a 
greater potential for plasticity and repair.  
Interestingly, our data suggest that versican may be more involved in the white matter 
component of H-I injury. Versican is secreted by OLs and its expression is developmentally 
regulated. Indeed, we observed reductions in the putative pre-OL marker O4 sulfatide in white 
matter of external capsule, corpus striatum and hippocampal fimbria at P11. The O4 antigen is a 
cell surface marker for both pre-OLs and adult progenitors in rat (Reynolds and Hardy 1997). 
Double-label immunohistochemistry revealed cells in the external capsule that co-expressed the 
O4 and NG2 antigens. While our quantification of O4 alone showing loss of immunoreactivity in 
white matter definitively demonstrates deep cerebral white matter loss, it is reasonable to suggest 
that at least a proportion of O4 immunoreactivity is specific to pre-OLs given the developmental 
stage and colocalization of these antigens. White matter versican expression was also reduced in 
ipsilateral external capsule at P11 and persisted to later endpoints, supporting the notion that 
versican may provide important signals to neighboring cells within developing white matter that 
are necessary to achieve adequate myelination. In the developing rodent, little brevican is 
expressed prior to P7. We were unable to detect changes in secreted brevican in white matter, 
possibly due to lack of sensitivity or low expression levels at this developmental stage. OLs are 
the major cell type responsible for the elevation in brevican expression that occurs from P7 to 
P14 (Ogawa et al. 2001) and therefore, while difficult to substantiate, it is tempting to speculate 
that the reductions in brevican after H-I observed at P11 were due, at least in part, to decreased 
deposition resulting from the early loss of pre-OLs.  
Taken together, these data provide a framework for further investigations into the role of 
lecticans in the progression of H-I pathology. The observed expression profiles suggest that the 
family of lecticans may not collectively subserve the same general functions. Instead, each of 
these molecules may contribute to distinct components of injury. Future studies investigating the 
regulatory mechanisms of these molecules, as well as their specific contributions to unique 
aspects of injury, may lead to novel approaches with the potential for highly selective therapeutic 
interventions. 
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Figure 1 
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Figure 1 Legend 
 
Rat brain regions selected for immunohistochemistry.  
Sections were collected 4 (P11), 14 (P21) and 21 (P28) days after  
H-I.  Photomicrographs were obtained from regions of cortex (CTX), corpus striatum (STR) and 
external capsule (EC) from coronal sections corresponding to approximately 0.70 mm rostral from 
bregma (top), and from hippocampus (HC) and hippocampal fimbria (FB) from sections 
corresponding to approximately 2.56 mm caudal from bregma (bottom). 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
Figure 2 Legend 
 
P7 H-I produces progressive lesions with variable severity. Cresyl violet stained coronal 
sections from animals subjected to H-I at P7. (A) Mild lesion 4 days after H-I displaying ventricular 
enlargement and slight hemispheric shrinkage. (B) Moderate lesion 14 days after H-I displaying 
ventricular enlargement, hemispheric shrinkage and cortical cavitary infarction. (C)  Severe lesion 
21 days after H-I displaying cortical and subcortical cavitary infarction with complete elimination of 
hippocampal structure. Quantification of lesion areas at 4 (P11), 14  (P21) and 21 (P28) days 
after H-I revealed a progressive injury profile represented as % decrease in total area of 
ipsilateral hemisphere (D), hippocampus (E), cortex (F) and corpus striatum (G) relative to 
contralateral control regions. Asterisks denote significant difference from P11 (p<0.05). 
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Figure 3 
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Figure 3 Legend 
 
Apoptosis and reactive gliosis after hypoxic-ischemic insult. Photomicrographs 
demonstrating double-labeling of (A) fractin and (B) GFAP in the ipsilateral hemisphere 4 days 
after H-I. (A) Caspase-generated cleavage fragment of β-actin (fractin) appearing in columns of 
cortex and in hippocampus, but not in white matter (25x magnification). Inset shows specific 
immunoreactivity in layer CA3 of hippocampus (400x magnification). (B) GFAP immunoreactivity 
in somatosensory cortex of the same section (200x magnification). (C-F) At P21, GFAP 
immunoreactivity is markedly increased in ipsilateral cortex of an animal demonstrating severe 
hippocampal cavitary infarction (D) compared to respective contralateral hemisphere (C) (25x 
magnification). 100x magnification shows a robust increase in GFAP immunoreactivity (F) relative 
to both contralateral control (E) and P11 ipsilateral cortex (B). White letters = contralateral control; 
red letters = ipsilateral lesion. 
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Figure 4 
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Figure 4 Legend 
 
Brevican deposition is associated with lesion progression. Photomicrographs demonstrating 
double-labeling of fractin (green) and brevican (red) after H-I. Brevican expression was reduced 4 
days after H-I in hippocampus (B) and cortex (D) compared to respective contralateral regions (A) 
and (C) and was coincident with elevations in fractin labeling (F, H) compared to respective 
contralateral areas (E,G). At 14 days after H-I, brevican expression was elevated in cortex (J, K) 
compared to contralateral cortex (I) and elevated in the border of the remaining hippocampal 
structure (L). White letters = contralateral control; red letters = ipsilateral lesion; magnification: (A, 
B, E, F) = 200x, (C, D, G, H, I - L) = 100x. 
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Figure 5 
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Figure 5 Legend 
 
Versican exhibits a unique expression profile with lesion progression. Photomicrographs 
demonstrating versican labeling after H-I. Versican expression was reduced 4 days after H-I in 
the dentate gyrus of the hippocampus (B), unchanged in cortex (D) and reduced in white matter 
of external capsule (F) compared to respective contralateral controls (A), (C) and (E). At 21 days 
after H-I, versican expression was unchanged in ipsilateral hippocampus (H), elevated in cortex 
(J) and markedly reduced in external capsule (L), compared to respective contralateral areas (G), 
(I), and (K). White letters = contralateral control; red letters = ipsilateral lesion; magnification = 
200x. 
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Figure 6 
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Figure 6 Legend 
 
White matter loss after hypoxia-ischemia.  
(A) Confocal micrograph showing double-labeling of O4 sulfatide (green) and GFAP (red) in 
corpus striatum of contralateral control. (B) Putative pre-OL markers O4 and NG2 colocalize 
(white arrows) on cell surfaces in external capsule. (C - H) Photomicrographs demonstrating 
white matter abundance after H-I, as indicated by O4 sulfatide immunoreactivity. O4 sulfatide was 
reduced 4 days after H-I in corpus striatum (C), external capsule (D) and hippocampal fimbria (E) 
compared to respective contralateral control areas (F), (G) and (H). White letters = contralateral 
control; red letters = ipsilateral lesion. Confocal scale bar = 50µm; C - H magnification = 100x. 
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Figure 7 
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Figure 7 Legend 
 
Quantification of external capsule white matter loss.  
Significant reductions occurred in all measures of O4+ immunoreactivity in external capsule 
including total area (EC Area), total intensity of labeling (O4 Intensity) and relative proportion of 
O4-labeled external capsule (Area Fraction). Asterisks denote significant difference from 
contralateral control (p < 0.05). 
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UAbstract 
 Hypoxia-ischemia (H-I) produces widespread neurodegeneration and deep cerebral white 
matter injury in the rat neonate. Resident immune cells may promote lesion progression by 
releasing proteases and other pro-inflammatory mediators. Gelatin-degrading matrix 
metalloproteinases (MMPs) participate in the loss of blood brain barrier integrity after injury, 
extracellular matrix (ECM) proteolysis and cytokine/chemokine activation. Altered ECM 
proteoglycan expression is associated with white matter injury. Thus, therapies targeting ECM 
degradation and progressive neuroinflammation may be beneficial in reducing H-I – induced 
neuropathy. Minocycline is neuroprotective in rat and has MMP-inhibitory properties. AG3340 is a 
small molecule MMP inhibitor with high selectivity for gelatinases. In this study, minocycline,  
AG3340 or vehicle were administered once daily for 6 days, beginning 24 hours after H-I, to 
determine whether gelatinase inhibition can limit H-I – induced injury. CD11b and glial fibrillary 
acidic protein (GFAP) immunopositive cells increased in ipsilateral cortex after treatment with 
vehicle alone, demonstrating microglia/macrophage recruitment and reactive astrogliosis, 
respectively. Cell death was indicated by Fluoro-Jade staining throughout the frontoparietal cortex 
and hippocampus. Treatment with minocycline or AG3340 inhibited microglia/macrophage 
recruitment, attenuated astrogliosis and reduced cell death when compared to vehicle alone. 
Thus, gelatin-degrading MMPs may be viable therapeutic targets to treat neonatal H-I injury. 
 
UKeywords:U matrix metalloproteinase; inhibitor; AG3340; minocycline; hypoxia; ischemia; 
neonate; inflammation; migroglia; macrophage  
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UIntroduction 
 
Exposure to a hypoxic-ischemic (H-I) insult has distinctive consequences in the 
developing brain. Immature vasculature and low baseline blood flow render the immature brain 
susceptible to even modest changes in perfusion pressure (Baier 2006). The maladaptive 
neurobiological response can be severe, resulting in deep cerebral white matter injury and 
substantial neuronal loss (Volpe 2001). Similar to the human condition, neonatal rodent models 
recapitulating these injuries show cortical and subcortical infarctions, impaired motor function 
(Bona et al. 1997; Jansen and Low 1996; Ten et al. 2003) and cognitive deficits (Arteni et al. 
2003; Ikeda et al. 2001; Young et al. 1986). Previous studies have linked oxidative stress (Back 
et al. 1998; Bernardo et al. 2003) and NMDA receptor  activation (Kaur et al. 2006) to white 
matter injury, while glutamatergic blockade has been shown to reduce H-I–induced infarction 
(David et al. 2003; Dingley et al. 2006; Puka-Sundvall et al. 2000) and white matter damage 
(Follett et al. 2000). Though excitotoxicity and free radical production are key contributors to the 
neuropathology of these lesions, there is a growing interest in identifying additional therapies to 
limit the progressive neuroinflammation that accompanies ischemic injury. 
Inflammation plays a key role in initiating pathological responses and potentiating 
neuronal damage after ischemia. The release of proteases from activated glia results in 
proteolytic degradation of basement membrane constituents (del Zoppo et al. 2007). This 
breakdown compromises the blood brain barrier, likely allowing entry of peripheral neutrophils 
and macrophages into the brain. These cell types, along with resident microglia, secrete 
proinflammatory cytokines and chemokines that further enhance microglia/macrophage 
recruitment to the injured site (Alvarez-Diaz et al. 2007). Matrix metalloproteinases (MMPs), the 
most well-studied extracellular matrix-degrading proteases, are capable of processing both TNF-
α (Gearing et al. 1994) and IL-1β (Schonbeck et al. 1998) to their biologically active forms. 
Several MMPs are elevated after cerebral ischemia and have been shown to degrade basement 
membrane proteins (Cunningham et al. 2005; Manicone and McGuire 2007). Gelatinases, in 
particular, are major contributors to ischemic pathology. In culture, MMP-2 – positive astrocytes 
produced MMP-9 when stimulated with either TNF-α or IL-1β (Gottschall and Yu 1995). In vivo, 
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MMP-2 expression increased in astrocytic endfeet while MMP-9 expression was localized to 
neutrophils and endothelial cells (Rosenberg et al. 2001). Other data showed elevated 
gelatinolytic activity that colocalized with neuronal laminin degradation, effects that were 
attenuated after administration of a highly selective MMP inhibitor (Gu et al. 2005). In agreement 
with these data, mice lacking MMP-9 showed improved outcomes that were directly related to 
reduced microglial activation (Svedin et al. 2007), attenuated blood brain barrier degradation 
(Gidday et al. 2005) and limited white matter damage (Asahi et al. 2001).  
In addition to cytokines and basement membrane proteins, MMPs are efficient at cleaving 
extracellular matrix (ECM) chondroitin sulfate proteoglycans (CSPGs). Lecticans, the family of 
aggregating CSPGs consisting of aggrecan, neurocan, versican, and brevican, are deposited as 
ECM in the brain, providing structural stability throughout the interstitial space and exerting 
effects on cellular adhesion and signaling (Yamaguchi 2000). Proteolytic processing of lecticans 
has been linked to H-I pathology in the rat neonate (Aya-ay et al. 2005). Furthermore, recent data 
indicates that white matter damage may be associated with reduced versican expression, while 
progressive neuronal damage correlates with lectican deposition in response to the injury 
(Leonardo et al. 2007). While lecticans are known substrates for ADAMTS (a disintegrin and 
metalloproteinase with thrombospondin repeats) proteases (Apte 2004; Dingley et al. 2006) and 
MMPs (Gottschall et al. 2005), little is known about the proteolytic regulation of lecticans after H-I.   
Taken together, these data underscore the potential involvement of MMPs in ischemic 
pathology and point to a specific role in enhancing the inflammatory microenvironment, thereby 
exacerbating injury through proteolytic cleavage of various substrates. Rodent knockout studies 
have proven useful in identifying MMP substrates in the ischemic brain. Although data show 
improved neuropathological outcomes, the need for novel therapeutic interventions remains. In 
this study, two compounds were selected to determine the effects of MMP inhibition on 
neuroinflammation and cell death after H-I. Minocycline, a tetracycline derivative known for its 
anti-inflammatory properties, is neuroprotective in several rat injury models (Cai et al. 2006; Fan 
et al. 2006; Wasserman and Schlichter 2007) and has recently been shown to exert MMP 
inhibition both in vitro and in vivo (Machado et al. 2006). AG3340, a small molecule hydroxamate-
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based inhibitor of MMPs, is efficacious in limiting tumor growth in rodent models (Alves et al. 
2001; Price et al. 1999) and was shown to be neuroprotective in rodents exposed to chronic 
ischemia (Nakaji et al. 2006). While both compounds demonstrate good oral bioavailability, 
AG3340 is a potent MMP inhibitor with high nanomolar affinity for gelatinases, specifically, when 
compared to the broad anti-inflammatory actions of minocycline. Results here show that 
administration of either minocycline or AG3340 at a clinically relevant time point reduced 
neuroinflammation and cell death. These data provide evidence that MMPs modulate the 
neuroinflammatory response to H-I and highlight the potential of targeting MMPs when 
developing treatment-based therapies to combat neonatal H-I injury. 
 
 
UMaterials and Methods 
 
Induction of Hypoxia-Ischemia 
All animal procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals with a protocol approved by the Institutional Animal Care and Use 
Committee at the University of South Florida. Neonatal Sprague-Dawley rats were birthed from 
time-pregnant dams (Harlan Labs). Dams and litters were maintained on a 12 hr light/dark cycle 
(7 am – 7 pm) and given access to food and water ad libitum. Litters from 2 dams were culled to 
10 pups per litter at postnatal day 1 (P1) and cross-fostered randomly between dams prior to 
each experiment. Two H-I experiments consisting of animals from 2 litters per experiment were 
used in this study. The H-I procedure was originally developed by Levine (Levine 1960) and 
reprised by Vannucci and colleagues (Rice et al. 1981; Vannucci et al. 1999) for use in the 
neonate. The H-I methodology was described in some detail previously (Leonardo et al. 2007). 
Briefly, the procedure entailed permanent unilateral ligation of the common carotid artery followed 
by transient exposure to hypoxia. P7 rats were anesthetized with 2.5% isofluorane, placed on a 
heating pad (37°C) and maintained at 350 ml/min of oxygen and 1.5% isofluorane with an 
interfaced scavenging system for the duration of the surgery. The right common carotid artery 
was exposed, isolated away from the vagus and ligated using a 6.0 nylon suture. The 
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musculature and skin were sutured, animals placed back with their corresponding dams for a 2 h 
recovery period and subsequently exposed to 8% oxygen/N B2B balanced for 90 min. During 
hypoxia, pups were placed into custom-made chambers that maintained a temperature of 37°C 
while permitting the water-saturated oxygen mixture to be dispensed at a constant flow rate (Aya-
ay et al. 2005). Pups were then returned to their respective dams until initiation of the treatment 
phase. 
 
Drug Treatment 
 Animals exposed to H-I were randomly assigned to receive either vehicle, minocycline 
(Sigma Aldrich, St. Louis, MO) or AG3340 (AG3340 was kindly provided by Dr. Peter Baciu, 
Allergan, Irvine, CA). Vehicle consisted of 50% DMSO + 25% propylene glycol in distilled water. 
Minocycline and AG3340 were dissolved in vehicle to obtain stock solutions of 13.5 mg/ml. Fresh 
stock solutions of drugs were prepared every 2 days. Pups were weighed each day and weight-
based injection volumes were calculated to yield a final dose of 45 mg/kg for each animal. 
Treatments were administered once daily (s.c.) for 6 days beginning 24 hours after H-I (P8). 
Animals were evaluated daily for signs of pain or discomfort, and no adverse effects were 
observed in response to either compound or vehicle alone. Following treatment, animals were 
sacrificed for histochemical analyses. 
 
Tissue Preparation 
For histochemical evaluation, tissues were collected 7 days after H-I (P14) as previously 
described (Leonardo et al. 2007). Animals were anesthetized with pentobarbital (60 mg/kg) and 
intracardially perfused with phosphate-buffered saline (PBS, pH 7.4) followed by 4% 
paraformaldehyde. Brains were removed and cryopreserved with increasing sucrose 
concentrations (15%, 30%), sectioned coronally on a cryostat at 30 µm thickness and thaw-
mounted onto Superfrost slides (Fisher Scientific, Suwane, GA) to achieve maximum 
preservation of morphology of the tissue surrounding the lesion. Serial sections were collected 
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throughout the brain beginning at approximately 1.2 mm rostral to bregma and ending at 
approximately 5.8 mm caudal to bregma.  
   
Histology and Immunohistochemistry 
Immunohistochemistry was performed as previously described (Leonardo et al. 2007) to 
assess reactive astrogliosis, MMP-cleaved proteoglycan fragment and microglia/macrophage 
recruitment to the injured site. Slides were rinsed with PBS, permeabilized and blocked for 60 min 
(3% Triton-X, 3% 1M Lysine, 10% NGS in PBS), incubated overnight with primary antibody at 
4˚C, incubated 60 min with secondary antibody at room temperature and coverslipped using 
Vectashield aqueous mounting media (Vector Labs, Burlingame, CA). Double-label 
immunohistochemistry was achieved by co-incubation with anti-mouse and anti-rabbit primary 
antibodies, and subsequent co-incubation with secondary antibodies conjugated to distinct 
fluorophores for each respective species of primary antibody.  
Primary antibodies used in these studies were mouse anti-glial fibrillary acidic protein 
(GFAP) (Roche Applied Science, Indianapolis, IN; 1:1000), affinity-purified rabbit anti-PLPDSR 
(custom produced by Sigma Genosys, St. Louis, MO; 1:250, CGGGPLPDSR conjugated to 
keyhole limpet hemocyanin for immunization and the same conjugated to Pierce Sulfolink 
(Rockford, IL) for affinity purification) and mouse anti-OX-42 (Serotec, Raleigh, NC; 1:300). 
Primary antibodies were visualized using either Alexa Fluor 488 (green) or Alexa Fluor 594 (red) 
secondary antibodies (Molecular Probes, Eugene, OR). Working concentrations for secondary 
antibodies were 1:3000 for OX-42 and 1:1000 for all other primary antibodies.   
The Fluoro-Jade stain identifies areas of cell death, predominantly degenerating neurons, 
and provides a positive quantitative marker as opposed to the absence of stain that is observed 
when using nissl stain. Fluoro-Jade was previously shown to be a more sensitive measure of cell 
death when compared to triphenyltetrazolium chloride (TTC). This method was adapted from 
Schmued and colleagues (Schmued et al. 1997) and subsequently detailed (Duckworth et al. 
2005). Tissues were prepared and mounted on glass slides as described. Slides were 
sequentially placed in 100% ethanol for 3 min, 70% ethanol for 1 min and deionized water for 1 
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min. Sections were oxidized for 15 min using 0.06% KMnO B4B solution followed by 3 brief rinses in 
PBS. Slides were then immersed in a 0.001% solution of Fluoro-Jade (Histochem, Jefferson, AR) 
in 0.1% acetic acid for 30 min, rinsed with PBS, dried for 20 min at 45˚C, cleared with xylene and 
coverslipped using DPX medium (Electron Microscopy Sciences, Ft. Washington, PA). 
 
Image Analyses and Quantification 
Images were acquired using a Zeiss Axioscope 2 (model #801572) microscope controlled 
by Openlab (Improvision Ltd, Lexington, MA) software, and photomicrographs were captured with 
a Zeiss Axicam Color (model #412-312) camera. All images subjected to direct comparisons were 
captured at the same exposure and digital gain settings to eliminate confounds of differential 
background intensity or false-positive immunoreactivity across sections. Immunoreactivity was 
quantified using NIH ImageJ software. Photomicrographs of sections from P14 rats were 
imported into ImageJ and two distinct methods were employed to best assess relative abundance 
of immunoreactivity. Histogram analyses were performed to assess astrogliosis. Total GFAP 
intensity values were calculated based upon the frequency of positive pixels that occurred within 
an intensity spectrum ranging from 0 (no immunofluorescence detected) to 256 (highest 
immunofluorescence intensity). For GFAP quantification, 2 cortical fields per section were 
selected for analyses. Cortical field selection was achieved by moving lateral from the most 
dorsal aspect of the corpus callosum (layers 1-4), and again moving medial-ventral to the 
adjacent field (layers 5-6). For cell death indicated by Fluoro-Jade stain, the entire cortex was 
traced and background subtraction was achieved by enhancing contrast until background 
particles were eliminated from the images. All sections were selected at fixed intervals throughout 
the bregma coordinates described previously.  
 
Statistical Analyses 
Data from all treatment groups were expressed as X ± SEM. For reactive astrogliosis and 
cell death, data were represented as aribitrary units (AUs) of total immunofluorescence intensity. 
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Group means were then subjected to a one-way ANOVA with “p value” set at 0.05. Pair-wise 
comparisons of group means were made using a Dunnett’s Multiple Comparison test. 
  
UResults 
 
Microglia/macrophages at the Cortical Lesion Site 
 Exposure to H-I initiates deleterious biochemical cascades that facilitate recruitment of 
proinflammatory cells to the lesion site. Previous data from our laboratory identified reactive 
astrogliosis as a major component of the injury response (Leonardo et al. 2007). To expand on 
those data, immunohistochemistry was performed to determine whether microglia/macrophages 
play as large a role in this process. Because microglia express MMPs and are recruited to injured 
sites, sections from non-treated and vehicle-treated animals (N = 5 per group) were labeled with 
anti-OX-42, an antibody that binds CD11b and is a macrophage/microglial marker. These same 
sections were double-labeled with anti-PLPDSR, an antibody that recognizes an MMP-derived 
neoepitope fragment of the proteoglycan versican (Fig. 1). Robust labeling of CD11b was 
localized to regions containing PLPDSR-positive cells (Fig. 2). Intense OX-42 immunoreactivity 
was restricted to the ipsilateral cerebral cortex (Fig. 2B) and was markedly elevated when 
compared to the contralateral control region (Fig. 2A). Some labeling was detected in the 
contralateral hemisphere but was faint and diffuse by comparison. Anti-PLPDSR 
immunoreactivity was also elevated in ipsilateral cortex (Fig. 2D), appearing as clusters of cells 
that were difficult to identify specifically, although they appeared to be neuronal. Though fewer 
PLPDSR-positive cells were detected when compared to OX-42, the versican fragment was not 
detected in the contralateral control hemisphere (Fig. 2C) and each of the ipsilateral clusters was 
present within regions that showed intense OX-42 immunofluorescence (Fig. 2E,F). These effects 
were not observed in animals treated with minocycline or AG3340.  
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Cell Death Is Associated with MMP-Cleaved Versican and Microglia/Macrophage 
Recruitment 
 Hypoxia-ischemia often produces cortical and subcortical cavitary infarctions over time 
that are not present up to 4 days after insult. Tissues from vehicle-treated animals (N = 5) were 
collected 7 days after H-I and stained with Fluoro-Jade to determine the degree of cell death 
present at this time (Fig. 3). Fluoro-Jade staining was prominent in the ipsilateral hemisphere. 
Signal appeared as columns in lower cortical layers, was diffusely distributed throughout the 
striatum and labeled hippocampal CA1-CA3 pyramidal neurons intensely. All other hippocampal 
fields were comparatively signal-free (Fig. 3A).  Importantly, Fluoro-Jade signal was present both 
in and adjacent to regions of OX-42 and PLPDSR immunoreactivity. The cortical 
neurodegeneration profile was consistent with elevated OX-42 and anti-PLPDSR 
immunoreactivity shown previously (Fig. 2). In hippocampus, OX-42 and anti-PLPDSR did not 
colocalize with Fluoro-Jade. Immunoreactivity for the MMP-cleaved fragment of versican was 
absent throughout Ammon’s horn, but appeared in the dentate gyrus (Fig. 3B). While increased 
OX-42 labeling was detected in the dentate gyrus (Fig. 3C), very little cellular colocalization was 
found with the PLPDSR antigen (Fig. 3D).   
 
Delayed Treatment Dampens Reactive Astrogliosis    
 Previous data demonstrated a robust astroglial response early after H-I in the neonate, 
indicating that reactive astrocytes are key players in neuroinflammation and respond upstream of 
severe infarction (Leonardo et al. 2007). To test whether inhibition of MMPs can reduce astrocyte 
reactivity after H-I, immunohistochemistry was performed 7 days after H-I to assess GFAP 
upregulation (Fig. 4). In general, low levels of GFAP were detected in contralateral cerebral 
cortex (Fig. 4A,D,G). GFAP immunoreactivity showed robust increases in ipsilateral cortex and 
appeared to be elevated in layers 5-6 (Fig. 4C,F,I) relative to layers 1-4 (Fig. 4B,E,H). Animals 
treated with vehicle alone showed robust increases in GFAP in layers 1-4 (Fig. 4B) and layers 5-6 
(Fig. 4C). This is consistent with the inflammatory response previously reported at an earlier 
endpoint. Astrogliosis was diminished after administration with either minocycline or AG3340. 
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While the observed effect of minocycline was most evident in cortical layers 1-4 (Fig. 4E), 
administration of AG3340 nearly abolished astrogliosis in layers 1-4 (Fig. 4H) and appeared more 
efficacious in layers 5-6 (Fig. 4I) when compared to minocycline (Fig. 4F).  Quantification was 
performed by analyzing photomicrographs (N = 8 per group, 5 sections per animal) for total 
GFAP immunoreactivity. Results showed significant reductions in GFAP immunoreactivity in 
cortical layers 1-4 (Fig. 4J) and layers 5-6 (Fig. 4K) of animals treated with either minocycline or 
AG3340 compared to treatment with vehicle alone (p<0.05), as measured by One-way ANOVA 
followed by Dunnett’s post-hoc analysis. Despite a clear trend, there was no significant difference 
in efficacy between treatments. 
 
Delayed Treatment Reduces Cell Death 
 Cell death was evident after H-I in animals treated with vehicle alone. To determine 
whether inhibition of MMPs provides neuroprotection, tissues were stained with Fluoro-Jade (Fig. 
5). Staining was absent from the contralateral hemisphere and very little non-specific background 
staining was detected (Fig. 5A,C,E). Tissues from animals treated with vehicle alone showed 
pronounced Fluoro-Jade labeling in ipsilateral cortex, and to a lesser degree, in corpus striatum 
(Fig. 5B). While striatal staining was inconsistent among vehicle-treated animals, intense 
columnar-shaped immunofluorescence was evident throughout the cerebral cortex in sections 
that ranged from the initial emergence of lateral ventricles to ventral hippocampus. Treatment 
with minocycline abolished this effect, showing little or no cortical Fluoro-Jade labeling (Fig. 5D). 
Administration of AG3340 also reduced Fluoro-Jade staining in cerebral cortex (Fig. 5F) when 
compared to sections from animals treated with vehicle alone, though this compound appeared to 
be less efficacious than minocycline. Quantification of cortical Fluoro-Jade staining was 
performed by analyzing photomicrographs (N = 5 per group, 5 sections per animal) for total area 
occupied by stain. Results showed a significant reduction in Fluoro-Jade staining after treatment 
with both compounds (Fig. 5G) when compared to treatment with vehicle alone (p<0.05), as 
measured by One-way ANOVA followed by Dunnett’s post-hoc analysis. Efficacy did not differ 
significantly between minocycline and AG3340. Tissues examined from each of these treatment 
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groups showed inconsistent staining profiles in corpus striatum and hippocampus and therefore 
were not subjected to quantitative analyses.  
 
Delayed Treatment Ameliorates the Microglia/Macrophage Response 
 To determine whether reduced cell death was associated with microglia/macrophage 
recruitment to the lesion site, immunohistochemistry was performed with anti-OX-42 to detect the 
CD-11b antigen present on cell membranes of microglia and macrophages (N = 5 per group). 
The results demonstrated a clear microglia/macrophage response to H-I (Fig. 6). Tissues from 
animals treated with vehicle alone showed increased OX-42 immunoreactivity in the ipsilateral 
cerebral cortex (Fig. 6B). CD11b labeling in contralateral control regions was faint and diffuse by 
comparison (Fig. 6A), indicating that OX-42 – positive cells were being recruited to the injured 
area. Treatment with minocycline ameliorated this effect, as ipsilateral OX-42 immunoreactivity 
(Fig. 6D) was indistinguishable from that observed in the contralateral control hemisphere (Fig. 
6C). OX-42 – positive cells were also greatly reduced in ipsilateral cortex of animals treated with 
AG3340 (Fig. 6F) relative to contralateral control (Fig. 6E).  
 
UDiscussion 
 
In models that perturb blood brain barrier integrity, the injury response often includes 
activation of reactive astrocytes, infiltration of peripheral macrophages and activation of resident 
microglia. Subsequent release of pro-inflammatory cytokines and elevations in protease activity 
likely contribute to cell death and deep cerebral white matter injury after H-I. The present study 
evaluated the degree of reactive astrogliosis, microglia/macrophage recruitment and cell death in 
a neonatal rat model. Treatment for 6 days with either minocycline or AG3340 demonstrated that 
both compounds are neuroprotective. Inhibition of MMPs dampened key inflammatory 
components of H-I injury, and that inhibition of the inflammatory response was associated with 
reduced cell death.  
 Glial scar formation, an early neurobiological response to cell death, may enhance the 
inflammatory response over time and exacerbate injury via cytokine and chemokine release from 
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reactive astrocytes, resident immune cells and peripheral leukocytes. Robust elevations in GFAP 
immunoreactivity were prominent throughout the cerebral cortex and were restricted to the 
ipsilateral hemisphere of animals treated with vehicle alone. Fluoro-Jade histochemistry revealed 
marked cell death that was anatomically consistent with heightened GFAP and OX-42 labeling. 
OX-42 – positive cells were abundantly distributed throughout the cortical lesion site. These cells 
could have been either peripheral macrophages that entered the CNS through a compromised 
blood brain barrier or resident microglia that were recruited to and proliferated near the injured 
site. There is currently no antibody available that distinguishes between microglia and 
macrophages. Indeed, gelatinases were shown to degrade dystroglycan after autoimmune 
encephalomyelitis, thus allowing the entry of peripheral leukocytes into the brain (Agrawal et al. 
2006). The majority of OX-42 – positive cells appeared to be ramified microglia, exhibiting spiny, 
dysmorphic morphology, yet many also displayed a rounder, amoeboid morphology indicative of 
an activated phenotype. While it is possible that the amoeboid cells were macrophages, there is 
some evidence indicating that microglia are the primary immune cells that respond to ischemic 
injury in the neonatal brain (Denker et al. 2007).  
Both microglia and peripheral macrophages secrete pro-inflammatory molecules and 
MMPs. In addition to degrading blood brain barrier constituents and myelin proteins, it has 
become increasingly evident that MMPs participate in complex injury responses through 
interactions with various cytokines and chemokines (Van Lint and Libert 2007). One potential 
mechanism is through ‘sheddase’ activity, where MMPs cleave ectodomains of membrane-bound 
cytokines such as TNF-α and IL1-β (Gearing et al. 1994; Gottschall and Yu 1995), thus releasing 
activated forms into the ECM. Other data shows that gelatinases cleave SDF-1 and various MCP 
chemokines (Overall et al. 2002), and SDF-1 accelerates proteolytic processing of syndecans by 
MMP-9 (Brule et al. 2006). Taken together, these data offer a potential mechanism by which 
gelatinase activity enhances neuroinflammation after H-I by facilitating immune cell chemotaxis. 
Interestingly, treatment with minocycline or AG3340 blocked the recruitment of 
microglia/macrophages, and therefore it is possible that the observed neuroprotective effects 
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associated with MMP inhibition were due to reducing chemokine gradients or direct binding of 
pro-inflammatory cytokines to cell surfaces.  
MMP-9 knockout mice showed reduced blood brain barrier degradation and white matter 
injury after experimental stroke (Asahi et al. 2001). Recent evidence also suggests that MMP-9 
expression colocalizes with activated resident microglia  (Svedin et al. 2007) and infiltrating 
leukocytes (Gidday et al. 2005; Romanic et al. 1998) in rodents subjected to cerebral ischemia. In 
agreement with these data, our results indicate that microglia/macrophage recruitment occurred 
at the lesion site where MMP activity was evident, ie. adjacent to MMP-cleaved versican, after 
treatment with vehicle alone. The absence of immune cell recruitment observed after treatment 
provides further evidence that MMP activity potentiates the inflammatory response. Because 
gelatinases efficiently degrade basement membrane proteins, it is possible that this effect 
occurred, at least in part, through preservation of the blood brain barrier. However, the majority of  
OX-42 – positive cells resembled microglia and this would suggest that resident immune cells, 
alone, may be sufficient to exacerbate inflammation in the brain, potentially by enhancing the 
migratory efficiency of microglia via ECM proteolysis. This is an interesting potential mechanism 
which, to date, has not been investigated. Previous studies using in vivo stroke models have 
implicated MMPs in blood brain barrier disruption and cerebral infarction. Pretreatment with the 
broad spectrum MMP inhibitor BB-94 reduced rtPA-induced blood brain barrier opening and 
subsequent mortality (Pfefferkorn and Rosenberg 2003), while pretreatment with an MMP-9 
neutralizing antibody reduced stroke-induced infarction (Romanic et al. 1998). A separate report 
demonstrated reductions in laminin degradation and neuronal apoptosis in the early phase of 
stroke after administration of the gelatinase-selective compound SB-3CT (Gu et al. 2005). Our 
data extend these findings by demonstrating a clear link between microglia/macrophage 
recruitment, astrocyte reactivity and gelatinase activity after H-I. Additionally, we showed that 
MMP inhibition at a delayed time point confers neuroprotection that persists 7 days after insult.  
Minocycline is known for its broad anti-inflammatory actions and has recently been 
shown to inhibit MMP activity in an in vivo stroke model (Machado et al. 2006). In this study, we 
sought to determine the degree to which MMPs, specifically, influence H-I pathology by selecting 
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two distinct compounds that exhibit differential anti-inflammatory actions and affinities for MMPs. 
Data show that minocycline reduced microglia/macrophage recruitment and cortical cell death. 
Two additional neonatal H-I studies have demonstrated short-term (Cai et al. 2006) and long-term 
(Fan et al. 2006) protection after treatment with minocycline. These experiments showed 
reductions in H-I - induced necrosis, in agreement with the reductions in Fluoro-Jade staining 
observed here. Importantly, these experiments differed from the present study in that animals 
were pretreated prior to insult and again immediately after occlusion. In the present study, 
treatment did not begin until 24 hours after the insult. Both minocycline and AG3340 reduced 
astrogliosis, and a trend toward increased efficacy was observed after treatment with AG3340. 
These data suggest that MMPs, and particularly gelatinases, may be key contributors to cortical 
astrocyte reactivity. 
 Lecticans are well-know MMP substrates and are richly deposited in and around lesioned 
tissue in several rodent brain injury models (Morgenstern et al. 2002). Versican was 
demonstrated to be expressed throughout the cortical infarction after H-I, while it was reduced in 
deep cerebral white matter (Leonardo et al. 2007). MMPs cleave lecticans efficiently, and 
increased secretion and activation of MMPs should result in proteolytic degradation of the ECM 
substrates. An antibody was generated against the neoepitope (PLPDSR) of versican that is 
exposed upon proteolytic cleavage by MMPs. Indeed, anti-PLPDSR-positive cells labeled 
intensely and were located adjacent to microglia/macrophages within the lesion core of animals 
treated with vehicle alone. In contrast, little immunoreactivity was observed for the MMP-cleaved 
fragment of versican after treatment with minocycline or AG3340, indicating that each of these 
compounds inhibited MMP activity either directly or indirectly. These data support the idea that 
microglia/macrophages may be primarily responsible for secreting MMPs after H-I. The MMP-
cleaved fragment of versican was detectable in white matter after H-I, yet the overall effects of 
treatment on PLPDSR immunoreactivity were subtle.  
Taken together, these data provide strong evidence that MMPs potentiate H-I pathology 
through inflammatory mediators. Future studies aimed at defining the early time course for 
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efficacy and the specific pro-inflammatory molecules involved should help to elucidate the specific 
sequence of neuroinflammatory events that contribute to H-I injury. 
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Figure 1 
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Figure 1 Legend 
 
Anti-PLPDSR. Custom antisera was synthesized (Sigma Genosys) against MMP-cleaved 
versican. The antibody recognizes the peptide PLPDSR that is conserved within the hylauronan 
binding region (HABR) of all versican isoforms. The custom peptide was designed using the 
versican V3 precursor protein (GenBank accession number UAAC26116U) and is located 
immediately upstream of the putative N-terminal MMP cleavage site (PLPDSR314  342FDAYCF). 
The specificities of the original antisera (Non-AP) and affinity purified antisera (AP) were verified 
by Western Blot using brain homogenate from adult rat and mouse.  Results showed a specific 
band in rat homogenate that migrated at the predicted position of ~43 kDa on SDS PAGE, and a 
second band at ~86 kDa indicating a doublet of the MMP-cleaved fragment. 
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Figure 2 
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Figure 2 Legend 
 
Microglia/macrophages are present with MMP-cleaved versican at cortical lesion site. 
Exposure to H-I at P7 resulted in elevated microglia/macrophages, as measured by OX-42 
immunoreactivity, in ipsilateral somatosensory cortex (B) compared to contralateral control (A). 
PLPDSR immunoreactive positive cells show MMP-cleaved fragment of versican at cortical lesion 
site (D) but absent in contralateral hemisphere (C). Merged image (E) demonstrates 
microglia/macrophages and MMP-cleaved versican fragment in the lesion core (F = 20x 
magnification). N = 5. Scale bars = 100 µm (A-E), 50 µm (F). 
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Figure 3 
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Figure 3 Legend 
 
Cell death is associated with MMP-cleaved versican and microglia/macrophage 
recruitment. Exposure to H-I at P7 resulted in robust Fluoro-Jade staining throughout cerebral 
cortex and in CA1-CA3 pyramidal cell layers of hippocampus (A), indicating severe cell death. 
PLPDSR (B) and OX-42 (C) immunoreactivity show MMP-cleaved versican and 
microglia/macrophage labeling in the dentate gyrus of hippocampus. Merged image shows 
distinct temporal staining with little colocalization in dentate gyrus of hippocampus (D). N = 5. 
Scale bars = 50 µm (A), 100 µm (B-D). 
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Figure 4 
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Figure 4 Legend 
 
Delayed treatment dampens reactive astrogliosis. P7 rat pups were exposed to H-I and 
treated with either vehicle, minocycline or AG3340 once daily for 6 days, beginning 24 hours after 
insult. (A-C) Astrogliosis, as measured by GFAP immunoreactivity, was markedly elevated in 
cortical layers 1-4 (B) and layers 5-6 (C) compared to contralateral control (A) after treatment with 
vehicle alone. Administration of either minocycline (D-F) or AG3340 (G-I) 24 hours after H-I 
reduced GFAP immunoreactivity in layers 1-4 (E,H) and layers 5–6 (F,I) compared to control 
hemisphere (D,G). GFAP immunoreactivity was significantly reduced in cortical layers 1-4 (J) and 
layers 5-6 (K) of animals treated with either minocycline or AG3340 compared to treatment with 
vehicle alone. N = 8, * = p<0.05. Scale bar = 50 µm. 
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Figure 5 
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Figure 5 Legend 
 
Delayed treatment reduces cell death. P7 rat pups were exposed to H-I and treated with either 
vehicle, minocycline or AG3340 once daily for 6 days, beginning 24 hours after insult. Animals 
treated with vehicle alone showed robust Fluoro-Jade labeling in ipsilateral cortex and corpus 
striatum (B). Fluoro-Jade staining was nearly abolished after treatment with minocycline (D) and 
greatly reduced after treatment with AG3340 (F) relative to vehicle alone (B). No labeling was 
detected in contralateral control regions (A,C,E). Quantification showed a significant reduction 
after treatment with either minocycline or AG3340 (G) compared to treatment with vehicle alone. 
N = 5, * = p<0.05. Scale bar = 100 µm. 
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Figure 6 
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Figure 6 Legend 
 
Delayed treatment ameliorates microglia/macrophage response. P7 rat pups were exposed 
to H-I and treated with either vehicle, minocycline or AG3340 once daily for 6 days, beginning 24 
hours after insult. Intense OX-42 immunoreactivity was evident throughout the ipsilateral cerebral 
cortex of animals treated with vehicle alone (B). Microglia/macrophage labeling was nearly 
abolished after treatment with minocycline (D) and was markedly reduced after treatment with 
AG3340 (F). OX-42 immunoreactivity in contralateral control regions was faint and diffuse by 
comparison (A,C,E). N = 5. Scale bar = 100 µm. 
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Abstract 
 Hypoxic-ischemic (H-I) insult during late gestational or early neonatal periods often 
manifests as cognitive and/or motor disturbances that appear early in development. Growing 
evidence indicates that targeting the neuroinflammatory response may be an avenue for 
therapeutic intervention. Resident microglia mediate the inflammatory response in brain by 
releasing proinflammatory molecules and proteases. Gelatinase matrix metalloproteinases 
(MMPs) activate proinflammatory cytokines and degrade basement membrane proteins after 
ischemia, thus permitting entry of peripheral monocytes/macrophages and enhancing 
neuroinflammation. To date, the relative contributions of resident and peripheral immune cells to 
brain injury in models that exhibit blood brain barrier degradation are not clear. Previous work 
showed that the selective gelatinase inhibitor AG3340 reduced neuroinflammation and 
neurodegeneration in vivo when administered at a delayed time point, yet the mechanisms and 
cell types involved remain unknown. The current study employed an ex-vivo model of oxygen 
glucose deprivation (OGD) to determine the cellular localization of MMP-9, and whether 
gelatinase inhibition could afford neuroprotection in the absence of peripheral immune cells. 
Organotypic hippocampal slices were exposed to 48 hrs of either normoxia or OGD in media 
containing vehicle, AG3340, or minocycline. Immunohistochemistry revealed that OX-42/MMP-9 
– positive cells were prevalent after OGD, while few were observed after normoxia. Surprisingly, 
neuronal expression of MMP-9 was ubiquitous in both normoxic and hypoxic slices. In situ 
zymography revealed increased gelatinase activity after OGD in non-treated and vehicle-treated 
slices compared to normoxic slices. Treatment with AG3340 or minocycline reduced gelatinolytic 
activity and Fluoro-Jade staining after OGD, indicating that dampening gelatinase activity reduced 
subsequent neurodegeneration. These results suggest that resident microglia may be sufficient to 
enhance the neuroinflammatory response and neurodegeneration profile after H-I, potentially 
through upregulation or secretion of MMP-9. Additionally, these data lend support to the selective 
targeting of gelatinase MMPs as a potential therapeutic approach to combat H-I injury. 
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Introduction 
Immature cerebral vasculature and low baseline blood flow render the immature brain 
inherently susceptible to changes in perfusion pressure (Baier 2006; Hamrick and Ferriero 2003). 
Because the developing vasculature adapts poorly, hypoxic-ischemic (H-I) insults that occur 
during the perinatal period initiate deleterious neurobiological responses. The resulting pathology 
includes cerebral white matter injury (Back et al. 2002; McQuillen and Ferriero 2004) and 
neurodegeneration (Vannucci et al. 1999), both of which are likely to result in loss of function. 
These injuries manifest early in development as motor disturbances and/or cognitive impairments 
(Back and Rivkees 2004; Folkerth 2005). Improvements in neonatal care have increased the 
number of infants who survive these insults, underscoring the need for novel approaches to 
combat H-I pathology. Similar to the human condition, neonatal rodents exposed to H-I exhibit 
cognitive deficits (Arteni et al. 2003; Ikeda et al. 2001; Young et al. 1986) and impaired motor 
function (Bona et al. 1997; Jansen and Low 1996; Ten et al. 2003). Previous work has 
demonstrated that oxidative stress (Back et al. 1998; Bernardo et al. 2003) and NMDA receptor 
activation (Kaur et al. 2006) contribute to white matter injury, while glutamatergic blockade 
immediately following H-I reduced white matter injury (Follett et al. 2000), H-I – induced infarction 
(Dingley et al. 2006) and DNA fragmentation (Puka-Sundvall et al. 2000). The destructive effects 
of excitotoxicity and free radical production are clear. Despite this fact, selective targeting of these 
mechanisms has failed to produce functional improvements in clinical trials. As the need for 
unique approaches is evident, accumulating evidence suggests that targeting neuroinflammatory 
mechanisms may be a promising avenue for therapeutic intervention.  
The role of resident microglia in modulating the inflammatory response is well-
documented in the developing brain (Chew et al. 2006). Following ischemic insult, activated 
microglia upregulate the expression of various cytokines and chemokines (Fukui et al. 2006; Kim 
1996; Van Lint and Libert 2007). Blood brain barrier degradation permits peripheral 
monocyte/macrophage entry into the brain and further enhances microglia/macrophage 
recruitment to the injured site (Alvarez-Diaz et al. 2007).  Data from numerous studies, both in 
vitro and in vivo, suggest that matrix metalloproteinases (MMPs) may be instrumental in the 
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production and maintenance of a proinflammatory microenvironment (del Zoppo et al. 2007). 
Astrocytes and microglia become activated within hours after ischemic insult. In vitro, MMP-9 
expression was induced in astrocytes after stimulation with either TNF-α or IL-1β (Gottschall and 
Yu 1995) and in microglia after stimulation with LPS (Rosenberg et al. 2001). Conversely, MMPs 
have been shown to process both TNF-α (Gearing et al. 1994) and IL-1β (Schonbeck et al. 1998) 
to their biologically active forms, while other data demonstrated a role for MMPs in chemokine 
signaling (Overall et al. 2002). These data suggest a complex regulatory system by which the 
concerted actions of gelatin-degrading MMPs and proinflammatory molecules modulate the 
neuroinflammatory response.  
Many groups have reported degradation of basement membrane proteins by MMPs after 
ischemia (Cunningham et al. 2005; Manicone and McGuire 2008). MMP-9 knockout mice showed 
improved outcomes that were associated with attenuated blood brain barrier degradation (Asahi 
et al. 2001; Gidday et al. 2005) and reduced microglial activation (Svedin et al. 2007). Other in 
vivo experiments revealed MMP-9 expression that was localized to neutrophils and endothelial 
cells, and showed elevated MMP-2 expression in astrocytic endfeet (Rosenberg et al. 2001). The 
latter expression profile places MMP-2 in the ideal position to proteolytically process basement 
membrane constituents. Indeed, cortical gelatinase activity increased after middle cerebral artery 
occlusion, and neuronal laminin degradation was associated with upregulated MMP-9 expression 
(Gu et al. 2005), evidence consistent with MMP proteolysis of basal lamina constituents.  
MMPs also contribute to extracellular matrix (ECM) reorganization through the proteolytic 
processing of chondroitin sulfate proteoglycans known as lecticans (Gottschall et al. 2005). 
Lecticans provide structural stability throughout the interstitial space and exert effects on cellular 
adhesion and signaling (Yamaguchi 2000). Proteolytic processing of lecticans has been linked to 
H-I pathology in the rat neonate (Aya-ay et al. 2005), with alterations in expression correlating 
with progressive white and gray matter injury (Leonardo et al. 2008). Very little is known 
regarding the specific effects of ECM proteolysis in neonatal H-I injury, though potential 
mechanisms may include the induction of cellular anoikis or the facilitation of 
microglia/macrophage migration.  
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Despite this gap in knowledge, it is likely that the migration of microglia/macrophages to 
the lesion site is achieved, at least in part, through proteolytic activity of gelatin-degrading MMPs. 
Recent data from our laboratory demonstrated that rat neonates exposed to H-I showed reduced 
astrogliosis, microglia/macrophage recruitment and neurodegeneration after delayed treatment 
with either AG3340, a small molecule hydroxamate-based inhibitor with high selectivity for 
gelatinases, or minocycline, a tetracycline derivative with anti-inflammatory and MMP-inhibitory 
properties (unpublished data). However, it was not clear whether the immune cells identified were 
resident cells of the brain or peripheral cells that entered the CNS through a compromised blood 
brain barrier. Additionally, the immediate effects of gelatinase activity after H-I remain unknown. 
Therefore, the present study addressed these questions by utilizing an ex-vivo model that lacks 
the peripheral immune cell response to insult. These experiments were conducted to assess 
gelatinase activity, to determine the cellular localization of MMP-9 and to test the hypothesis that 
inhibition of gelatin-degrading MMPs can suppress OGD (oxygen glucose deprivation) – induced 
neurodegeneration.  
 
Materials and Methods: 
Organotypic Slice Culture 
All animal procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals with a protocol approved by the Institutional Animal Care and Use 
Committee at the University of South Florida. Neonatal Sprague-Dawley rats were birthed from 
time-pregnant dams (Harlan Labs, Indianapolis, IN). Dams were maintained on a 12 hr light/dark 
cycle (7 am – 7 pm) and given access to food and water ad libitum. Organotypic slice cultures 
were prepared using a method previously described (Stoppini et al. 1991), with slight adaptations. 
Rat pups (postnatal day 8 – 10) were removed from their dams, anesthetized with CO B2,B and 
decapitated. Brains were removed and intact hippocampi were dissected in cold isotonic buffer 
(136.89 mM NaCl, 5.37 mM KCl, 169 nM Na B2BHPO B4B, 22.04 nM KHB2BPO B4B, 27.52 nM glucose, 59.01 
mM sucrose). Whole hippocampi were sliced at 400 µm thickness using a McIlwain Tissue 
Chopper (Mickle Laboratory Engineering Co. Ltd. Gomshall, Surrey, England). Slices were 
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quickly transferred back into a petri dish containing cold isotonic buffer. Mechanical separation 
was achieved by expelling 1 mL of isotonic buffer into the dish and repeating until the majority of 
slices appeared to be autonomous. Only slices that appeared thin and translucent were selected 
for culture. Using blunt forceps, individual slices were then transferred into droplets of isotonic 
buffer (1 slice per droplet) and chilled for 90 min at 4˚C to seal membranes that were presumed to 
be damaged from the initial chopping. Cultures were maintained on Millicell CM (Millipore Corp., 
Billerica, MA) inserts that provide mechanical support for slice viability while allowing passive 
diffusion of media and tissue factors. Inserts were placed in 12 well plates containing 1.1 mL of 
organotypic slice culture media (OTCC; 500 mL neurobasal media, 10 mL B-27 supplement, 6.25 
mL L-glutamine (Invitrogen, Carlsbad, CA)) per well and allowed 30 min to equilibrate. After 
equilibration, 15 µL of OTCC was added onto each insert. Slices were then carefully transferred 
into this media and allowed to settle onto the inserts. All slices were cultured for 14 days in a 
standard tissue culture incubator at 37˚C and received partial media changes every 3-4 days (500 
µL OTCC) prior to experimentation.  
  
Oxygen Glucose Deprivation 
 Organotypic slices were subjected to 48 hrs of normoxia or oxygen glucose deprivation 
(OGD) to determine first, whether gelatinase activity is associated with neurodegeneration, and 
second, whether selective gelatinase inhibition can reduce cell death after OGD in the absence of 
peripheral immune cell effects. Slices were assigned to 1 of 2 exposures (normoxia or OGD) and 
1 of 3 treatments (vehicle, AG3340, or minocycline). Immediately prior to exposure, inserts were 
transferred into new 12 well plates containing vehicle, AG3340 (AG3340 was kindly provided by 
Dr. Peter Baciu, Allergan, Irvine, CA), or minocycline (Sigma Aldrich, St. Louis, MO). Vehicle 
consisted of 0.1% DMSO in Delbecco’s Modified Eagles Medium (DMEM; Mediatech, Herndon, 
VA) for normoxia or DMEM without glucose (Invitrogen, Carlsbad, CA) for OGD. Stock solutions 
of minocycline and AG3340 were prepared, aliquotted and stored at -80˚C prior to experiments. 
Fresh working solutions were prepared for each experiment. Stocks were diluted in the 
appropriate vehicles immediately prior to each experiment to yield final working volumes of 1.1 
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mL per well. Working concentrations were as follows: AG3340 = 3 µM; minocycline = 30 µM. 
Drug concentrations were selected based on doses that were previously shown to reduce 
neuroinflammation and neurodegeneration in vivo (unpublished data). Cultures were maintained 
in a standard tissue culture incubator during the normoxia exposure and a hypoxic chamber (CBS 
Scientific Co. Inc., Del Mar, CA) held at 37˚C during the OGD exposure.  
 
Histology and Immunohistochemistry 
Immunohistochemistry was performed as previously described (Leonardo et al. 2008) to 
determine the cellular localization of MMP-9 in organotypic hippocampal slices after exposure to 
normoxia or OGD. Immediately following the 48 hr exposure, inserts were transferred into 12 well 
plates containing 1.1 mL of 4% paraformaldehyde and slices were fixed for 24 hrs. Inserts were 
then submerged in phosphate-buffered saline (PBS, pH 7.4). Slices were carefully dissociated 
from the inserts using a small paint brush, mounted onto Superfrost Plus slides (Fisher Scientific, 
Suwane, GA) and dried overnight at 20˚C. For immunohistochemistry, slices were rinsed with 
PBS, permeabilized and blocked for 60 min (3% Triton-X, 3% 1M Lysine, 10% NGS in PBS), 
incubated overnight with primary antibody at 4˚C. On day 2, slices were washed with PBS, 
incubated 60 min with secondary antibody at 20˚C, washed again and coverslipped using 
Vectashield aqueous mounting media (Vector Labs, Burlingame, CA). Double-label 
immunohistochemistry was achieved by co-incubation with anti-mouse and anti-rabbit primary 
antibodies, and subsequent co-incubation with secondary antibodies conjugated to distinct 
fluorophores for each respective species of primary antibody.  
Primary antibodies used in these studies were mouse anti-glial fibrillary acidic protein 
(GFAP) (Roche Applied Science, Indianapolis, IN; 1:1000), mouse anti-OX-42 (Serotec, Raleigh, 
NC; 1:300) and rabbit anti-MMP-9 (Chemicon, Temecula, CA, 1:200). Primary antibodies were 
visualized using either Alexa Fluor 488 (green) or Alexa Fluor 594 (red) secondary antibodies 
(Molecular Probes, Eugene, OR). Working concentrations for secondary antibodies were as 
follows: 1:3000 for OX-42; 1:1000 for GFAP and MMP-9.  
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Fluoro-Jade Staining  
Fluoro-Jade staining was performed to determine whether treatment with AG3340 or 
minocycline improves organotypic hippocampal slice viability after exposure to OGD. The Fluoro-
Jade stain identifies dead and degenerating neurons, thus providing a positive quantitative 
marker as opposed to the absence of labeling that is observed when using Nissl stain. Fluoro-
Jade was previously shown to be a more sensitive measure of cell death when compared to 
triphenyltetrazolium chloride (TTC) (Duckworth et al. 2005). This method was adapted from 
Schmued and colleagues (Schmued et al. 1997) and subsequently detailed (Duckworth et al. 
2005). Slices were prepared and mounted on glass slides as described for histology. Slides were 
sequentially placed in 100% ethanol for 3 min, 70% ethanol for 1 min and deionized water for 1 
min. Sections were oxidized for 15 min using 0.06% KMnO B4B solution followed by 3 brief rinses in 
PBS. Slides were then immersed in a 0.001% solution of Fluoro-Jade (Histo-Chem, Jefferson, 
AR) in 0.1% acetic acid for 30 min, rinsed with PBS, dried for 20 min at 45˚C, cleared with xylene 
and coverslipped using DPX medium (Electron Microscopy Sciences, Ft. Washington, PA). 
 
In Situ Zymography 
In situ zymography was performed to assess gelatinase activity in organotypic 
hippocampal slices after exposure to normoxia or OGD. Immediately following the exposure 
period, slices were dissociated from the inserts and mounted onto glass slides as described in 
histology. Slices were dried briefly prior to incubation. Slides were coated with 50 µl of DQ gelatin 
(Invitrogen, Carlsbad, CA), coverslipped and incubated 90 min at 37˚C to allow for enzymatic 
cleavage of the gelatin. DQ gelatin is quenched with FITC molecules that emit fluorescence when 
the gelatin is enzymatically cleaved by MMP-2 or MMP-9. Following incubation, fluorescence was 
visualized at a wavelength of 480 nm.  
 
Image Analyses and Quantification 
For quantification, images were acquired using a Zeiss Axioscope 2 microscope 
controlled by Openlab (Improvision Ltd, Lexington, MA) software, and photomicrographs were 
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captured with a Zeiss Axicam Color camera. All images subjected to direct comparisons were 
captured at the same exposure and digital gain settings to eliminate confounds of differential 
background intensity or false-positive fluorescent signal across sections. Fluorescence was 
quantified using NIH ImageJ software. Photomicrographs of organotypic hippocampal slices were 
imported into ImageJ and background subtraction was achieved by enhancing contrast until 
background particles were eliminated from the images. To control for size differences between 
slices, fluorescence values were calculated by dividing the total fluorescence by the total area of 
the slice, thus yielding percent of total area occupied by fluorescent signal. 
Additional high-power micrographs were captured for MMP-9 immunohistochemistry and 
in situ zymography to verify cell-specific expression of MMP and to better determine the cellular 
localization of gelatinase activity.  These images were obtained using a Leica SP-2 confocal 
microscope and Leica LCS software.  
 
Statistical Analyses 
Data from all treatment groups were expressed as X ± SEM of the percent area occupied 
by fluorescent signal. Group means were then subjected to two-way ANOVAs with “p value” set 
at 0.05. Pair-wise comparisons of group means were made using Bonferroni post-hoc tests. 
 
Results 
Cellular Localization of MMP-9  
 Matrix metalloproteinases are known to be involved in the neuropathological response to 
ischemia. While MMP-2 activity contributes to peripheral monocyte/macrophage infiltration 
through blood brain barrier disruption, MMP-9 activity may contribute to neuronal damage by 
enhancing inflammation associated with resident microglia. Immunohistochemistry was employed 
to characterize the cellular localization of MMP-9 in an ex-vivo model of hypoxia-ischemia that 
lacks peripheral immune cell infiltration. Organotypic hippocampal slices were cultured for 14 
days and exposed to normoxia or OGD. MMP-9 expression was ubiquitous in slices exposed to 
normoxia (Fig. 1). GFAP – positive astrocytes were prevalent throughout the slices and 
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predominantly displayed the typical morphology associated with the quiescent state (Fig. 1B,E). 
Immunoreactivity for MMP-9 was detected in some astrocytic cell bodies and processes (Fig. 1A-
C). The majority of MMP-9 expression, however, did not appear to colocalize with astrocytes (Fig. 
1D-F). To determine whether basal MMP-9 expression occurs in resident immune cells, slices 
were double-stained with anti-MMP-9 and anti-OX-42, an antibody that recognizes the cd11b 
antigen that is commonly expressed on the cell surfaces of microglia and macrophages. OX-42 – 
positive cells displayed the classic amoeboid morphology associated with activated microglia 
(Fig. 1H), consistent with previous data indicating that these cells exhibit a heightened activation 
state under culture conditions. Interestingly, MMP-9 immunoreactivity did not appear to colocalize 
with microglia in most cases (Fig. 1G-I). Instead, MMP-9 expression appeared to be 
predominantly neuronal in normoxic slices. 
 The expression of MMP-9 was altered in slices that were exposed to OGD (Fig. 2). 
Astrogliosis and microglial activation are hallmarks of the neuroinflammatory response to H-I. 
Indeed, hypertrophic astrocytes were observed in slices subjected to OGD. GFAP 
immunoreactivity was intense in astrocytic cell bodies and processes throughout the slices (Fig. 
2A). Similar to the expression profile observed in normoxic slices, MMP-9 immunoreactivity 
predominantly localized to cell bodies that were not GFAP – positive (Fig. 2B,C). Exposure to 
OGD resulted in increased OX-42 immunopositive cells (Fig. 2D). Clusters of these cells were 
generally observed adjacent to the hippocampal cell layers. MMP-9 expression was again 
observed in cells with neuronal morphology. Importantly, MMP-9 expression (Fig. 2E) colocalized 
with OX-42 – positive microglia (Fig. 2F), indicating that exposure to OGD resulted in upregulated 
MMP-9 expression in these resident immune cells. 
 
Treatment with AG3340 or Minocycline Attenuates Gelatinase Activity 
 To determine whether increased MMP-9 expression after OGD was associated with 
increased gelatinolytic activity, in situ zymography was performed on slices exposed to normoxia 
or OGD (Fig. 3). Gelatin-cleaved fluorescence was observed in slices exposed to normoxia (Fig. 
3A,C,E), indicative of basal MMP-2 and/or MMP-9 activity in organotypic slice culture. Gelatinase 
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activity was primarily localized in the nuclei and throughout the cytoplasm, consistent with 
previous data (Amantea et al. 2008). Many of the fluorescent cell bodies appeared to have a 
twisted morphology indicative of a more activated phenotype when compared to the ramified 
phenotype characteristic of resting microglia. After exposure to OGD, slices showed increased 
fluorescent labeling (Fig. 3B,D,F). As in normoxic slices, gelatinase activity was found to be 
nuclear and cytoplasmic. However, compact, amoeboid cells resembling activated microglia were 
ubiquitous after OGD (Fig. 3D) in contrast to the twisted cells observed after normoxia. 
Additionally, a much greater fluorescent intensity was observed after OGD and was also localized 
to cellular processes when viewed at higher magnification (Fig. 3F). Gelatin-cleaved fluorescence 
in normoxic slices was faint by comparison and was limited to nuclei and cytoplasm (Fig. 3E).  
 Previous data from our laboratory showed that administration of either AG3340 or 
minocycline at a delayed time point after H-I conferred neuroprotection (unpublished data). To 
expand on those data, experiments were performed to assess the activity of gelatin-degrading 
MMPs in response to OGD, and to test the MMP-inhibitory efficacy of these compounds. In situ 
zymography was performed on organotypic slices that were exposed to 48 hrs of normoxia or 
OGD in media containing vehicle, AG3340, or minocycline. Quantification of gelatin-cleaved 
fluorescence was performed by analyzing photomicrographs (N = 2 cultures; 3 slices per group) 
for percent of total hippocampal area occupied by fluorescent signal (Fig. 4). Gelatin-cleaved 
fluorescence was increased in slices exposed to OGD (27.6% +/- 2.9%) relative to normoxia 
(15.5% +/- 4.1%; p<0.01) after treatment with vehicle alone. Furthermore, activity was 
significantly attenuated in slices exposed to OGD and treated with AG3340 (16.1% +/- 2.6%; 
p<0.01) or minocycline (20.1% +/- 3.4%; p<0.05) relative to those treated with vehicle alone. 
There were no significant differences between normoxia and OGD for either treatment, though 
trends for increased gelatin-cleaved fluorescence were evident.     
 
Treatment with AG3340 or Minocycline Reduces Neurodegeneration 
 To determine whether gelatinase activity was directly associated with neurodegeneration 
after OGD, organotypic slices were exposed to 48 hrs of normoxia or OGD in media containing 
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vehicle, AG3340, or minocycline and were stained with Fluoro-Jade (Fig. 5). Basal levels of 
Fluoro-Jade stain were detected in normoxic slices after all treatments. Staining was most 
prominent in the hippocampal neuronal cell layers but was also present in surrounding tissue. In 
general, Fluoro-Jade staining was more intense and occupied larger areas in slices exposed to 
OGD and treated with vehicle alone (Fig. 5D) relative to their normoxic controls (Fig. 5A). Fluoro-
Jade staining was elevated in slices exposed to OGD and treated with AG3340 (Fig. 5E) when 
compared to normoxic controls (Fig. 5B). In contrast, slices treated with minocycline and exposed 
to OGD showed faint staining that occupied smaller areas of total tissue (Fig. 5F) resembling 
normoxic controls (Fig. 5C).   
Quantification of Fluoro-Jade staining was performed by analyzing photomicrographs (N 
= 3 cultures; 6 slices per group) for percent of total hippocampal area occupied by fluorescent 
signal (Fig. 6). Fluoro-Jade staining was significantly elevated in slices exposed to OGD (21.5% 
+/- 2.4%) relative to normoxia (8.0% +/- 1.0%; p<0.01) after treatment with vehicle alone. 
Quantification also revealed a significant increase in staining after OGD (10.7% +/- 1.2%) relative 
to normoxia (5.8% +/- 0.3%; p<0.05) in slices treated with AG3340, yet the degree of staining was 
significantly lower when compared to those treated with vehicle alone (p<0.01). Fluoro-Jade was 
also reduced after OGD in slices treated with minocycline (7.7% +/- 1.1%) relative to those 
treated with vehicle alone (5.1% +/- 1.1%; p<0.01), and the degree of staining was not statistically 
different from normoxic controls.  
      
Discussion 
 H-I insults produce neural sequelae characterized by substantial white matter injury and 
neurodegeneration. Inflammation mediates the delayed injury response in ischemic brain. Both 
peripheral and resident immune cells may aid in proinflammatory signaling, yet the relative 
contributions of infiltrating leukocytes and resident microglia have yet to be elucidated. Gelatin-
degrading MMPs proteolytically process endothelial cell junction proteins (Reijerkerk et al. 2006; 
Rosenberg and Yang 2007) and inflammatory cytokines (Ito et al. 1996; Schonbeck et al. 1998). 
Previous reports have demonstrated that gelatinases modulate neuroinflammation (Gidday et al. 
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2005; Svedin et al. 2007), blood brain barrier degradation (Asahi et al. 2001; Back et al. 1998) 
and cell death (Asahi et al. 2000; Lee et al. 2004) after ischemia. However, the association of 
MMPs with neuroinflammation and injury in the absence of peripheral immune cell effects has not 
been investigated to date. Therefore, the present study was conducted to determine whether 
selective gelatinase inhibition can confer neuroprotection in an ex vivo model of H-I that lacks 
peripheral immune cell involvement. Results showed that MMP-9 expression was upregulated in 
organotypic hippocampal slices after 48 hrs exposure to OGD. Furthermore, gelatinase activity 
and neurodegeneration increased in slices exposed to OGD, effects that were attenuated when 
slices were incubated with media containing either AG3340 or minocycline.  
To our knowledge, this is the first study utilizing organotypic slice culture methodology to 
investigate the effects of ischemic insult in brain, and the first to link cell viability with MMP activity 
in the absence of peripheral immune cell effects. Immunohistochemistry revealed that MMP-9 
expression was ubiquitous in organotypic slices and was associated with plasma membranes. 
Normoxic slices showed moderate expression in astrocytes and little expression in OX-42 – 
positive microglia. The size and morphology of MMP-9 – positive cell bodies, coupled with the 
general lack of colocalization with GFAP or OX-42, suggests that MMP-9 expression was 
predominantly neuronal. In contrast, MMP-9 colocalized with OX-42 – positive cell bodies and 
GFAP – positive astrocytic processes in slices exposed to OGD. MMP-9/cd11b - expressing cells 
were consistent with activated microglia such that the cell bodies were smaller and displayed an 
amoeboid morphology. These data are in agreement with previous studies that localized 
gelatinase activity to neurons and glia (Amantea et al. 2008; Lee et al. 2004; Lu et al. 2008). 
Additionally, the increased MMP-9 expression profile after OGD suggests that the insult induced 
microglial expression of MMP-9.  
 In situ zymography experiments demonstrated that there is basal gelatinase activity in 
organotypic hippocampal slices. Gelatin-cleaved fluorescence was predominantly limited to cells 
with neuronal morphology, consistent with the neuronal expression profile of MMP-9 in normoxic 
slices. Gelatinase activation in normoxic slices is likely a response to cellular injury from the slice 
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preparation itself. The presence of Fluoro-Jade staining in normoxic slices supports this 
explanation.  
Upon exposure to OGD, gelatin-cleaved fluorescence was markedly increased. 
Gelatinase activity was not limited to neurons after OGD. Instead, activity appeared in cells with 
amoeboid microglial morphology and also localized to cellular processes. The cellular phenotypes 
associated with these processes were difficult to determine but were most likely astrocytes, as 
MMP-9 immunoreactivity appeared to localize to some astrocytic processes after OGD. Several 
groups have previously reported gelatinase expression in activated astrocytes in vitro (Apodaca 
et al. 1990; Muir et al. 2002; Rosenberg et al. 2001).  
 Both AG3340 and minocycline were efficacious in attenuating OGD – induced gelatinase 
activity and Fluoro-Jade staining. Gelatinase activity, therefore, correlated with increased 
neurodegeneration, and both compounds were able to reduce associated neuronal cell death. 
Consistent with these data, AG3340 was previously shown to be neuroprotective in the adult 
brain after ischemia (Nakaji et al. 2006). AG3340 is a small molecule hydroxamate-based MMP 
inhibitor with high selectivity for gelatinases. Minocycline has also been shown to possess MMP-
inhibitory properties (Machado et al. 2006) but acts primarily as an anti-inflammatory agent. This 
compound has also improved outcomes in several rodent injury models (Cai et al. 2006; Fan et 
al. 2006; Wasserman and Schlichter 2007). Taken together with the cellular expression profile of 
MMP-9, these data suggest a direct link between gelatinase activity and neuroinflammation in 
response to H-I. While the selective inhibition of active MMP-9 and/or MMP-2 was sufficient to 
confer neuroprotection, the fact that minocycline was equally efficacious supports the notion that 
the resident immune cell response may facilitate MMP expression or activation.  
Importantly, both compounds showed efficacy at concentrations that reduced recruitment 
of cd11b - positive cells and decreased neurodegeneration in an in vivo model of neonatal H-I 
(unpublished data). In the previous study, drug was administered 24 hrs after H-I and all data was 
collected 7 days post-insult. There are two differences worthy of mention. The former study 
consisted of a 6 day treatment period that primarily assessed the delayed immune response. 
Additionally, it could not be determined whether OX-42 – positive cells were of CNS origin, as 
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there is currently no available antibody that differentiates between resident microglia and 
peripheral macrophages. The present study exploited a model that lacks the peripheral immune 
cell response to determine whether gelatinase activity is of resident immune cell origin, and 
whether heightened MMP activity is associated with neuronal cell death during the early 
neuroinflammatory response to H-I. Other advantages to this model are that it is more conducive 
to mechanistic experimentation and more closely resembles the microenvironment in brain when 
compared to primary cell culture or mixed-glial culture. Taken together, these data indicate that 
gelatinase activity is linked to the resident microglial response within the first 48 hrs after OGD, 
and that inhibition of gelatinase activity reduces neurodegeneration in an ex vivo model of H-I 
injury. Thus, selective targeting of gelatin-degrading MMPs may be an avenue for therapeutic 
intervention to combat H-I neuropathies.  
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Figure 1 
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Figure 1 Legend 
 
Basal MMP-9 expression. Confocal micrographs show cellular expression of MMP-9 (A,D,G), 
GFAP (B,E) and OX-42 (H) after 48 hrs exposure to normoxia. Basal MMP-9 expression was high 
and primarily localized to cell bodies (D,G). Merged images show MMP-9 expression in astrocyte 
processes and cell bodies (C), though the majority of astrocytes either did not express MMP-9 or 
expression was low (F). OX-42 – positive microglia display the activated phenotype in normoxic 
slices (H). Merged image shows OX-42 did not colocalize with MMP-9 (I). Magnification = 63x. 
Arrows indicate colocalization.  
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Figure 2 
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Figure 2 Legend 
 
Neuroinflammatory response to oxygen glucose deprivation. Confocal micrograph shows 
hypertrophic astrocytes (A) after 48 hrs exposure to OGD, while MMP-9 expression is limited to 
distinct cell bodies (B). Merged image shows MMP-9 did not colocalize with astrocytes (C). OGD 
results in robust expression of cd11b (D) and MMP-9 (E). Merged image shows MMP-9 
colocalizes with microglia (F). Magnification = 63x. Arrows indicate colocalization.  
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Figure 3 
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Figure 3 Legend 
 
 
 
Gelatinase activity is elevated after oxygen glucose deprivation. Confocal micrographs show 
in situ zymography in organotypic hippocampal slices after 48 hrs exposure to normoxia or OGD. 
Basal gelatinase activity was detected in normoxic cells (A,C,E) and was increased after 
exposure to OGD (B,D,F). Gelatinase activity was localized to many distinct cellular morphologies 
after OGD (F) when compared to normoxia (E). Magnification = 20x (A,B); 40x (C,D); 63x (E,F).  
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Figure 4 
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Figure 4 Legend 
 
Quantification of in situ zymography. Gelatin-cleaved fluorescence was quantified in 
organotypic hippocampal slices after exposure to normoxia or OGD in media containing vehicle, 
AG3340, or minocycline. Slices treated with vehicle alone showed a significant increase in 
fluorescent signal after exposure to OGD relative to normoxic controls (p<0.01). Gelatinase 
activity was significantly reduced in slices exposed to OGD and treated with either AG3340 
(p<0.01) or minocycline (p<0.05) relative to those treated with vehicle alone. N = 6. * indicates 
significant from normoxia; # indicates significant from OGD + vehicle.  
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Figure 5 
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Figure 5 Legend 
 
Neurodegeneration occurs after oxygen glucose deprivation. Organotypic hippocampal 
slices exposed to normoxia or OGD in media containing vehicle, AG3340, or minocycline were 
stained with Fluoro-Jade. Basal Fluoro-Jade staining was detected in slices exposed to normoxia 
after all treatments (A-C). Staining was markedly elevated in slices exposed to OGD and treated 
with vehicle alone (D) compared to normoxic controls (A), and this effect was attenuated in slices 
exposed to OGD and treated with either AG3340 (E) or minocycline (F). Scale bar = 100 µm. 
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Figure 6 
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Figure 6 Legend 
 
Quantification of Fluoro-Jade staining. Fluorescent stain was quantified in organotypic 
hippocampal slices after exposure to normoxia or OGD in media containing vehicle, AG3340, or 
minocycline. Fluoro-Jade staining was significantly increased in slices exposed to OGD and 
treated with vehicle alone (p<0.01) or AG3340 (p<0.05) relative to their respective normoxic 
groups. There was no significant difference between slices treated with minocycline and exposed 
to either normoxia or OGD. Furthermore, the increase in Fluoro-Jade observed in slices treated 
with vehicle alone and exposed to OGD was significantly attenuated in those treated with either 
AG3340 (p<0.01) or minocycline (p<0.01). N = 6. * indicates significant from normoxia; # 
indicates significant from OGD + vehicle.   
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Conclusions 
Improvements in medical care over past decades have increased the numbers of 
premature and low birth weight infants that survive H-I insults. Because there is a rising incidence 
in diseases associated with these events, it is critical to develop effective therapies to treat the 
various resulting neuropathies. The most common experimental model used to recapitulate 
clinical perinatal H-I insults produces neurodegeneration and deep cerebral white matter injury in 
the neonatal rat brain (Towfighi et al. 1995; Vannucci et al. 1999), leading to impaired cognitive 
and motor functioning. Excitotoxicity, free radical production, glial scar formation and 
neuroinflammation all contribute to the resulting pathology (Ashwal and Pearce 2001), yet the 
precise manner in which these processes are regulated has yet to be elucidated. ECM 
proteoglycans and matrix-degrading proteases exert effects on cell viability and may be 
associated with either protective or destructive processes after H-I. ECM constitutes the majority 
of brain parenchyma. Lectican deposition, in particular, is elevated in several rodent injury models 
(Beggah et al. 2005; Jones et al. 2003a; Jones et al. 2003b; Mayer et al. 2005; Vorisek et al. 
2002). Turnover of ECM proteins is modulated by matrix-degrading metalloendopeptidases. Both 
ADAMTSs (Cross et al. 2006; Tian et al. 2007) and MMPs (del Zoppo et al. 2007; Gu et al. 2005; 
Rosenberg et al. 2001) have been associated with pathological states in brain. Despite these 
facts, the relative contributions of lecticans, ADAMTSs and MMPs to inflammation and cell death 
in the neonatal brain remain elusive.  
The present study was designed to investigate several aspects of H-I pathology. The first 
series of experiments were conducted to characterize cellular damage and neuroinflammation in 
the P7 rat after exposure to H-I, and to determine if cell death and inflammation were associated 
with alterations in proteoglycan expression. Data from these experiments led to two additional 
objectives and subsequent series’ of experiments. The first of these was to determine whether 
treatment with AG3340, a selective inhibitor of gelatin-degrading MMPs, could confer 
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neuroprotection when administered at a delayed time point after insult, and to compare the 
efficacy with that of the well-known anti-inflammatory compound minocycline. These experiments 
showed that in addition to demonstrating efficacy, MMP inhibition significantly attenuated the 
classic neuroinflammatory response that is associated with progressive injury in this model, 
revealing a temporal relationship between the neuroinflammatory response and cell death within 
the first week after insult. The final series of experiments were designed to determine whether 
selective gelatinase inhibition could neuroprotect in an ex vivo H-I model that lacks peripheral 
immune cell involvement, thus providing insight into the relative contributions of resident microglia 
and gelatinase activity to the inflammatory sequelae. Data here showed that administration of 
AG3340 significantly reduced gelatinase activity and neuronal cell death after 48 hrs exposure to 
OGD. These data provide evidence that gelatinase activity originates from resident cells of the 
brain, thus lending support to the notion that gelatinases contribute to injury in the absence of 
peripheral leukocytes and through mechanisms distinct from blood brain barrier degradation. 
 
Brevican and Versican Deposition after H-I  
In response to H-I insult, energy failure resulting from reduced cellular uptake of oxygen 
and glucose leads to the production of free oxygen/nitrogen radicals and eventually cell death 
(Shalak and Perlman 2004). The delayed response to insult, though less understood, involves 
neuroinflammatory mechanisms initiated by both resident and peripheral immune cells, including 
the production and secretion of proinflammatory cytokines and chemokines, as well as glial scar 
formation. The glial scar acts as a barrier to separate injured tissue from surrounding viable 
tissue. Though considered to be an inherent protective mechanism, the glial scar restricts 
neuroplasticity and therefore reduces the capacity for regeneration of lesioned tissue (Silver and 
Miller 2004). Therefore, the first objective of the current study was to characterize the expression 
of brevican and versican at selected endpoints after insult (P11 (4 days), P21 (14 days), and P28 
(21 days)), and to determine the association of these proteoglycans with neuroinflammation and 
cell death.  
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Immunohistochemical staining of reactive glia and fractin, the caspase-derived proteolytic 
fragment of β-actin, allowed for the detection of pathology at the cellular level in the absence of 
grossly observable infarctions. Animals sacrificed at later endpoints (P21 and P28) showed 
severe cortical and subcortical cavitary infarctions that were rarely present at P11, indicating that 
the resulting injury was progressive. Elevated immunoreactivity for GFAP and fractin was evident 
in cortex and hippocampus at P11 and was also observed at later endpoints. The fact that both 
GFAP and caspase-cleaved β-actin were observed at P11 and preceded cavitary infarction 
supports the notion that while reactive astrogliosis is associated with injury, apoptosis accounts 
for some degree of progressive cortical and hippocampal cell death. Loss of deep cerebral white 
matter was also observed at the early endpoint. Immunoreactivity for the putative pre-OL marker 
O4 was reduced in white matter of the external capsule, corpus striatum and hippocampal 
fimbria. A closer inspection revealed a population of cells in the external capsule that co-
expressed the O4 and NG2 antigens. Pre-OLs are selectively vulnerable to H-I when compared 
to their mature, myelinating counterparts (Back et al. 2001). Data from a previous study indicated 
that OLs which co-express these antigens are likely to be either pre-OLs or immature OLs 
(Reynolds and Hardy 1997). Therefore, while disruptions of axoglial junctions may have 
accounted for the observed reductions, the presence of O4 and NG2 – positive cells at this stage 
in development suggests that at least a proportion of the total O4 immunoreactivity was specific 
to pre-OLs. The death of pre-OLs at this stage in development is detrimental, as myelination of 
neural tracts will be disrupted if these cells fail to differentiate into mature, myelinating OLs.  
In general, lecticans inhibit neurite outgrowth and therefore might be expected to act as 
non-permissive substrates to tissue repair in this model (Asher et al. 2002). Brevican and 
versican are developmentally regulated in the rat neonate (Yamaguchi 2000). Upon investigation, 
the two proteoglycans showed distinct responses to H-I and alterations in expression were 
associated with distinct regions in brain. Brevican immunoreactivity was reduced at P11 in cortex 
and hippocampus, confirming data previously published by our laboratory (Aya-ay et al. 2005). 
Only modest changes in versican expression were detected in gray matter at P11 and were 
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limited to hippocampus. In contrast, versican expression was reduced in the external capsule at 
P11, where no changes in brevican immunoreactivity were detected.  
A key feature of glial scar formation and maintenance is the upregulation of lectican 
expression, thus conferring inhibitory properties that restrict neural plasticity in several models of 
brain injury (Galtrey and Fawcett 2007). Intense immunoreactivity for both brevican and versican 
were evident in gray matter by P21. Previous reports have documented elevated lectican 
expression in the injured adult rat cortex. For example, the expression of both brevican (Jaworski 
et al. 1999) and versican (Asher et al. 2002) were increased in cortical stab wound tissue. This 
upregulated expression in response to injury, and in association with glial scarring, is consistent 
with the expression patterns shown here at P21 and P28. Despite these consistencies, it is 
noteworthy that the latter study reported increased versican expression 7 days after injury, while 
no changes in cortical versican were detected in the current study at P11. Because the current 
investigation did not include the P14 endpoint, it is difficult to interpret whether these data are, in 
fact, conflicting. However, reduced plasticity that is characteristic of adult rodents may result in an 
accelerated response to injury when compared to younger animals which display a greater 
potential for plasticity and repair. For this reason, care should be taken when comparing data 
from neonatal and adult injury models.  
Though lectican deposition was clearly increased in ipsilateral cortex at P21 and P28, the 
presence of severe cavitary hippocampal infarcts at these endpoints prevented any direct 
comparisons between hemispheres. However, brevican and versican expression were detected 
in ipsilateral hippocampi, and deposition occurred along the perimeter of the remaining 
hippocampal structures. Thus, the general expression profile in gray matter at later endpoints, 
together with elevations in astrogliosis and caspase-cleaved β-actin, provides evidence that 
increased expression and deposition of these lecticans may aid in glial scar formation resulting 
from extensive gray matter injury.  
Importantly, brevican and versican expression were altered in distinct regions of brain. 
Given the progressive injury that occurs in this model, cellular anoikis (Grossmann 2002) induced 
by proteolytic cleavage of lecticans may render neighboring cells susceptible to injury due to loss 
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of ECM signals or trophic support. O4 immunoreactivity was reduced in white matter at P11. 
Reduced white matter versican at both P11 and P21 supports the notion that versican may 
provide important signals that are necessary for immature OLs to differentiate into the mature, 
myelinating phenotype. Interestingly, fractin immunoreactivity was low in the selected white 
matter regions. These results would suggest that the loss of versican may contribute to cell death 
through mechanisms that are distinct from traditional caspase-mediated apoptotic signaling. A 
recent study in rat using a similar neonatal H-I model showed that the differentiation of pre-OLs 
was arrested 4 days after insult through mechanisms that were not associated with apoptosis. In 
these experiments, O4 – positive degenerating OLs were significantly increased up to 7 days 
after insult (Segovia et al. 2008). Although this group also reported significant increases in 
activated caspase-3 at this endpoint, there are important differences. In contrast to the current 
study, this group exposed rats to H-I at P3. By P10, caspase-3 immunoreactivity was reduced 
relative to P7 while OL degeneration remained elevated relative to controls. Therefore, when 
comparing this study to the current study, it is difficult to interpret whether the involvement of 
caspases is temporally related to the timing of the insult or the developmental stage of the animal. 
Regardless, the former study supports a mechanism that is distinct from caspase-mediated 
apoptosis and may explain the lack of fractin in white matter observed here. However, it is also 
possible that the anti-fractin antibody lacked the sensitivity to detect a lesser degree of β-actin 
cleavage than that which was observed in cortex and hippocampus. This explanation would also 
be supported by the heightened injury profile of these regions relative to that which was observed 
in white matter.  
Another interesting finding was that no changes in brevican expression were detected in 
white matter. This may have been due to either lack of sensitivity or low expression levels at this 
developmental stage. However, another explanation may account for this unexpected finding. OL 
progenitors migrate from the SVZ to white and gray matter regions throughout the brain (Levison 
and Goldman 1993). In contrast to versican, which is secreted not only by OLs but also by 
astrocytes, OLs are the major source of brevican from P7 to P14 (Ogawa et al. 2001). Based on 
proximity, OLs arrive at deep cerebral white matter targets earlier than most gray matter regions. 
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Therefore, it is tempting to speculate that reduced brevican expression in gray matter at P11 was 
due, at least in part, to decreased OL migration resulting from the early loss of pre-OLs.  
 
ADAMTSs, Lectican Turnover and Pre-OL Susceptibility to H-I 
 Data from the characterization experiments demonstrated that the deposition brevican 
and versican was altered after H-I. These results provided strong evidence that lecticans are 
involved in the formation and maintenance of the glial scar in this model, yet the unique 
spatiotemporal expression profiles observed at P11 prompted many questions as to the precise 
roles of these molecules in providing signaling and support to injured cells of the brain. As such, 
several additional studies were performed to gain insight into the mechanisms by which ECM 
lecticans are regulated following an ischemic event. Because lecticans are considered to be the 
major substrates for ADAMTS proteases (Flannery 2006; Porter et al. 2005), we hypothesized 
that activation or inhibition of ADAMTSs in response to the insult may have accounted for the 
altered expression profiles observed. Hence, the susceptibility of pre-OLs to H-I injury would be 
attributed to increased expression or activation of ADAMTSs, resulting in elevated ADAMTS-
mediated proteolysis of lecticans in developing white matter. In contrast, inhibition of these 
proteases over time via compensatory negative feedback mechanisms would explain the 
accumulation of proteoglycan in glial scar.  
The subsequent series of experiments were designed using multiple approaches. 
Immunohistochemistry was performed to determine whether ADAMTS cleavage of brevican was 
elevated in those regions that showed reduced expression at P11. For these experiments, an 
antibody was raised against the neoepitope of brevican (EAVESE) that is exposed in rat upon 
cleavage by ADAMTSs (Yuan et al. 2002). Regions of brain previously selected for 
immunohistochemical studies were dissected from a separate group of animals exposed to H-I, 
and biochemical assays were performed from brain homogenates to quantify cleaved fragments 
of brevican and versican. Concurrent with these experiments, primary pre-OLs were cultured to 
further investigate the role of CSPGs in pre-OL differentiation and susceptibility to OGD. In these 
experiments, proteoglycan stripe assays were performed in which OLs were seeded onto poly-L-
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lysine coverslips that were previously streaked with known concentrations of purified 
proteoglycan from rat brain.  
The data from these experiments, however, were not consistent with the expected 
outcomes. While it was hypothesized that EAVESE immunoreactivity would be elevated in cortex 
and hippocampus, supporting the notion that the reduction in brevican observed in these regions 
occurred as a result of proteolytic degradation by ADAMTSs, no changes in EAVESE expression 
were evident in cortex or hippocampus. Western Blots revealed that some animals showed 
increased cleavage fragments in ipsilateral regions relative to contralateral controls. Despite 
these data, the overall effects were variable and inconsistent. The final prediction was that pre-OL 
cultures would grow better on proteoglycan stripes relative to poly-L-lysine, consistent with the 
idea that proteoglycans are necessary substrates for pre-OLs as they differentiate into mature, 
myelinating cells. Although pre-OLs were able to grow on proteoglycan, quantification revealed 
that these cells actually grew better on the poly-L-lysine substrate. Taken together, these results 
demonstrated that ADAMTS activity is not likely to be a critical mediator of cell viability in this 
model, particularly at the early endpoint. Rather, a more plausible explanation for the expression 
data is that the reduced deposition of brevican and versican at P11 is simply an effect of cell 
death, whereby a proportion of OLs and/or astrocytes were no longer present to secrete these 
proteins into the ECM.  
Despite these unexpected results, other data from our laboratory, as well as previous 
reports from various rodent injury models, indicated that MMP activity may exert detrimental 
effects on the developing brain by contributing to the neuroinflammatory response to injury. 
Although MMPs have been investigated in ischemic models, little work has been done to 
elucidate the precise mechanisms by which MMPs contribute to inflammation and cell death after 
H-I in the rat neonate. 
 
The Effects of Anti-Inflammatory and MMP-Inhibitory Compounds in vivo 
Hypoxic-ischemic insults produce neural sequelae characterized by white matter injury 
and neurodegeneration. Previous experiments from our laboratory showed that GFAP was 
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elevated in the ipsilateral cortex of animals sacrificed 24 hrs after H-I. In addition, dense pockets 
of microglia/macrophages were identified with anti-ED-1, an antibody that recognizes the cell 
surface antigen CD68 (supplemental Fig. 1), and were found to be localized to regions containing 
astrogliotic cells. These experiments not only demonstrated that the neuroinflammatory response 
had begun within the first 24 hrs after insult, but also that MMPs were upregulated within in the 
ischemic hemisphere in cells with microglial morphology (supplemental Fig. 2). Gelatin-degrading 
MMPs proteolytically process endothelial cell junction proteins (Reijerkerk et al. 2006; Rosenberg 
and Yang 2007) and inflammatory cytokines (Ito et al. 1996; Schonbeck et al. 1998), causing a 
second, delayed opening of the blood brain barrier which promotes extravasation and entry of 
peripheral monocytes and macrophages (Wetzel 2005). Taken together with the prolonged 
astrogliosis (elevations in GFAP at P21 and P28) and progressive infarctions that were observed 
in rats exposed to H-I at P7, it is likely that the neuroinflammatory response persists for weeks 
after the initial insult and promotes cell death. In the clinical population, the current lack of 
effective therapies to treat neonatal H-I highlights the importance of discovering new targets for 
pharmacological intervention. In experimental models, few compounds have shown efficacy when 
administered after the insult. As such, therapeutics that target key elements of the delayed 
immune response may prove beneficial in mitigating neural injury.   
The second series of experiments evaluated the efficacy of two compounds in reducing 
reactive astrogliosis, microglia/macrophage recruitment and neurodegeneration in the rat neonate 
after H-I. Treatment for 6 days with either minocycline or AG3340, beginning 24 hrs after insult, 
demonstrated that both compounds were neuroprotective. Inhibiting inflammation, as with 
minocycline, or gelatin-degrading MMPs, as with AG3340, dampened key inflammatory 
components after H-I. Furthermore, inhibition of the inflammatory response was associated with 
reduced Fluoro-Jade staining, suggesting a link between immune cell recruitment and 
neurodegeneration. Immunohistochemistry revealed marked elevations in astrogliosis (GFAP) 
and microglia/macrophage recruitment (OX-42) throughout the ipsilateral cerebral cortex of 
animals treated with vehicle alone relative to contralateral controls. Fluoro-Jade staining indicated 
that cortical cell death was anatomically consistent with heightened GFAP and cd11b labeling, 
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suggesting that neurodegeneration was associated with the recruitment of immune cells to the 
lesion site. In addition, microglia/macrophage recruitment occurred in cortical regions where 
PLPDSR immunoreactivity was detected, demonstrating the presence of active MMPs in close 
proximity to these immune cells. These data are consistent with recent evidence indicating that 
MMP-9 expression colocalizes with activated resident microglia (Svedin et al. 2007). Little 
immunoreactivity was observed for the MMP-cleaved fragment of versican after treatment with 
minocycline or AG3340, indicating that each of these compounds inhibited MMP activity either 
directly or indirectly. Currently, there is no commercially available antibody that distinguishes 
between resident microglia and peripheral macrophages. While most cells that expressed cd11b 
appeared to be ramified microglia, many also displayed the amoeboid morphology indicative of 
an activated phenotype. Due to blood brain barrier disruption that most certainly occurs in this 
model, cells that expressed the cd11b cell surface antigen could have been either of these two 
cell types.  
Both minocycline and AG3340 reduced astrogliosis and neurodegeneration, and a trend 
toward increased efficacy was observed after treatment with AG3340. These data suggest that 
MMPs, and particularly gelatinases, may be key contributors to cortical astrocyte reactivity. 
However, it cannot be determined whether astrogliosis is a response to cell death or contributes 
to cell death. Minocycline exerts anti-inflammatory actions and was previously shown to inhibit 
MMP activity in an in vivo stroke model (Machado et al. 2006). Specifically, this study reported 
reductions in H-I - induced necrosis. These data are consistent with the reductions in Fluoro-Jade 
staining shown here after treatment with minocycline, as well as with the MMP-inhibitor AG3340. 
Two additional neonatal H-I studies have demonstrated short-term (Cai et al. 2006) and long-term 
(Fan et al. 2006) protection after treatment with minocycline. In the present study, minocycline 
was selected for two specific purposes. As the neuroprotective effects of minocycline are well 
documented, this treatment group served as a positive control. More importantly, however, 
inclusion of the minocycline group allowed for a comparison of efficacy between a compound that 
exerts broad anti-inflammatory effects and a compound that specifically inhibits MMPs in the 
absence of any other known functions. Administration of minocycline reduced 
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microglia/macrophage recruitment and cortical neurodegeneration, in agreement with the 
previous studies. However, the present study differed significantly from those mentioned 
previously in terms of treatment. In the previous reports, animals were pretreated prior to insult 
and again immediately after occlusion. In the present study, treatment did not begin until 24 hours 
after the insult, a more clinically relevant time point when considering the nature of perinatal H-I 
injury and the difficulty in making an early diagnosis.  
Previous experiments using in vivo stroke models have demonstrated not only that MMP 
activity compromises the blood brain barrier, but also that blocking MMP activity improves the 
neuropathological outcome. MMP-9 knockout mice showed reduced blood brain barrier 
degradation and white matter injury after experimental stroke (Asahi et al. 2001). Laminin 
degradation and neuronal apoptosis were reduced in the early phase of stroke after 
administration of the gelatinase-selective compound SB-3CT (Gu et al. 2005). Pretreatment with 
the broad spectrum MMP inhibitor BB-94 reduced rtPA-induced blood brain barrier opening and 
subsequent mortality (Pfefferkorn and Rosenberg 2003), while pretreatment with an MMP-9 
neutralizing antibody reduced stroke-induced infarction (Romanic et al. 1998). In general, the 
neuroprotective effects of interfering with MMP activity shown previously are consistent with the 
improved outcomes demonstrated here after the administration of either minocycline or AG3340. 
Interestingly, the association between dampened immune cell recruitment and reduced neuronal 
cell death in the present study occurred after treatment with either of two distinct compounds, and 
both compounds showed similar efficacy. Therefore, data here extend previous findings by 
demonstrating that immune cell responsiveness and MMP activity may subserve either the same 
signaling pathways or distinct, but convergent signaling pathways that ultimately result in 
neuronal cell death. Additionally, these data show a clear association between 
microglia/macrophage recruitment, astrocyte reactivity and gelatinase activity after H-I, indicating 
that MMP activity likely promotes neuroinflammation after the initial injury.  
In acknowledgement of previous data related to blood brain barrier degradation, it is 
possible that the effects of AG3340 were due, at least in part, to protection of the basement 
membrane. However, the majority of cd11b – positive cells resembled resting, inactivated 
 142
microglia. This would suggest that resident immune cells, alone, may be sufficient to exacerbate 
inflammation in the brain. Several other mechanisms may account for the protective effects of 
gelatinase inhibition. One potential mechanism by which this could occur is through reduced ECM 
proteolysis, thus diminishing the migratory capacity of microglia. This is a speculative possibility 
which, to date, has not been investigated. Despite this fact, the presence of intensely-labeled 
PLPDSR – positive cells in close proximity to microglia/macrophages within the cortical lesion site 
indicated that MMP cleavage of versican had occurred. Thus, the possibility that MMP-mediated 
ECM degradation could promote immune cell recruitment is, at the very least, plausible. This 
scenario would involve the secretion of MMPs by immune cells in response to immune cell 
activation, followed by MMP-mediated ECM proteolysis to allow for enhanced immune cell 
migration to injured sites within the brain. 
Both microglia and peripheral macrophages secrete pro-inflammatory molecules and 
MMPs. In addition to degrading blood brain barrier constituents and myelin proteins, it has 
become increasingly evident that MMPs participate in complex injury responses through 
interactions with various cytokines and chemokines (Van Lint and Libert 2007). One potential 
mechanism is through ‘sheddase’ activity, where MMPs cleave ectodomains of membrane-
associated effector molecules. For example, TNF-α (Gearing et al. 1994) is a substrate for 
gelatin-degrading MMPs. Conversely, both TNF-α and IL1-β have been shown to activate 
gelatinases (Gottschall and Yu 1995). Subsequent studies demonstrated that gelatinases cleaved 
SDF-1 and various MCP chemokines (Overall et al. 2002), and SDF-1 accelerated the proteolytic 
processing of syndecans by MMP-9 (Brule et al. 2006). Therefore, minocycline and/or AG3340 
may exert effects on chemokine gradients through a variety of mechanisms. This scenario seems 
more likely for minocycline, a known anti-inflammatory agent, while much less is known regarding 
the effects of MMP inhibition on cytokine and chemokine signaling in vivo. Nonetheless, the 
relative efficacies of minocycline and AG3340 in reducing the recruitment of immune cells to the 
lesion site lend further support to these mechanisms of MMP-inhibition. 
Taken together, data from these experiments provide strong evidence that attenuating 
the neuroinflammatory response provides neuroprotection at a delayed time point after injury. 
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Evidence also suggests that the efficacy of gelatinase inhibition is linked to neuroinflammatory 
responses, including reactive astrogliosis and the recruitment of resident microglia, peripheral 
macrophages, or both cell types.  
 
MMP Activity in Brain Contributes to Injury in the Absence of Peripheral Leukocytes 
 Data from the previous experiments, while encouraging, prompted additional questions 
as to the precise role of the peripheral immune system after H-I. Gelatinases degrade endothelial 
cell junction proteins (Reijerkerk et al. 2006; Rosenberg and Yang 2007) and activate 
proinflammatory cytokines (Ito et al. 1996; Schonbeck et al. 1998). Previous reports 
demonstrated a role for these proteases in neuroinflammation (Gidday et al. 2005; Svedin et al. 
2007), blood brain barrier degradation (Asahi et al. 2001; Back et al. 1998) and cell death (Asahi 
et al. 2000; Lee et al. 2004) after ischemia. Resident microglia are among the first cells to 
become activated in response to ischemic injury, acting as phagocytes to remove cellular debris 
from the brain parenchyma (Lai and Todd 2006) and releasing various cytokines (Fukui et al. 
2006; Kim 1996). Activated astrocytes, characterized by increased expression of GFAP, also 
migrate to the injured site. Though the specific functions of reactive astrocytes are not clear, both 
astrocytes and microglia are capable of exacerbating the inflammatory response through the 
secretion of proinflammatory cytokines and chemokines (Chew et al. 2006). As such, these cells 
likely contribute to neonatal H-I injury. Therefore, while AG3340 and minocycline showed efficacy 
in reducing immune cell recruitment and neurodegeneration, the precise mechanisms by which 
these compounds achieve these effects are difficult to elucidate using in vivo models. 
Recent evidence suggests that MMP-9 expression colocalizes with both activated 
resident microglia (Svedin et al. 2007) and infiltrating leukocytes (Gidday et al. 2005; Romanic et 
al. 1998) in rats subjected to cerebral ischemia. Each of these cell types elicits proinflammatory 
responses. Thus, in vitro models are necessary to determine the relative effects of the 
endogenous and exogenous immune cells on neuronal cell death after H-I. 
The objectives of the final series of experiments were twofold: to determine whether 
minocycline or AG3340 confer neuroprotection in an ex vivo model of H-I that lacks peripheral 
 144
immune cell involvement, and to determine the association of gelatinase activity with the cellular 
sources of MMP-9 in the ischemic brain. Results showed a shift in cellular MMP-9 expression that 
was concomitant with upregulated gelatinase activity in organotypic hippocampal slices after 48 
hrs exposure to OGD. Furthermore, these measures were associated with increased 
neurodegeneration, as measured by Fluoro-Jade staining. Gelatinase activity was significantly 
attenuated in slices that were exposed to OGD and incubated with media containing either 
AG3340 or minocycline, and these compounds significantly reduced neurodegeneration.  
 In situ zymography in normoxic slices revealed that basal gelatinase activity is present in 
this culture system. Gelatin-cleaved fluorescence was predominantly limited to cells with neuronal 
morphology, consistent with the neuronal expression profile of MMP-9 in normoxic slices. 
Gelatinase activation in normoxic slices indicates a tissue response to injury from the slice 
preparation since basal gelatinase activity is low in the intact brain. Fluoro-Jade staining was also 
present in slices exposed to normoxia, supporting this contention. Gelatin-cleaved fluorescence 
was significantly increased in slices exposed to OGD. Activity appeared in cells that appeared to 
be of microglial and neuronal lineage, though cell types were not confirmed using 
immunohistochemical methods. Specifically, these included amoeboid cells typical of activated 
microglia and triangular cell bodies that may have been neurons or astrocytes. Cellular processes 
that appeared to be astrocytic also showed activity. In normoxic slices, localization appeared to 
be almost exclusively neuronal, in agreement with previous studies that localized gelatinase 
activity predominantly to neurons (Amantea et al. 2008; Lee et al. 2004; Lu et al. 2008). 
 While gelatinases include both MMP-2 and MMP-9, the latter is most associated with 
neural injury (Wetzel 2005) and has previously been shown to contribute to injury of hippocampal 
neurons in response to ischemia (Lee et al. 2004). In general, MMP-9 immunoreactivity was 
ubiquitous and localized to plasma membranes in organotypic slices. Interestingly, little 
colocalization was observed with the microglia cell surface antigen cd11b in normoxic slices. 
However, some GFAP – labeled astrocytes did express MMP-9. The vast majority of MMP-9 – 
positive cell bodies, however, appeared to be neuronal. This was determined based on the size 
and morphology of cell bodies, coupled with the general lack of colocalization with GFAP or 
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cd11b. After OGD, a shift in expression was observed such that MMP-9 immunoreactivity 
colocalized with many cd11b – positive cells, though the majority of MMP-9 expression remained 
neuronal. MMP-9/cd11b - expressing cells were consistent with activated microglia such that the 
cell bodies were smaller and displayed an amoeboid morphology. MMP-9 immunoreactivity also 
localized to some astrocytic processes, consistent with previously studies that have reported 
gelatinase expression in activated astrocytes in vitro (Apodaca et al. 1990; Muir et al. 2002; 
Rosenberg et al. 2001). Additionally, the increased MMP-9 expression profile after OGD suggests 
that the insult expression of MMP-9. Some evidence suggests that microglia are the primary 
immune cells that respond to ischemic injury after MCAO in the neonatal rat brain (Denker et al. 
2007), supporting the notion that microglia may initiate deleterious signaling cascades that are 
dependent upon MMP proteolysis. 
 To our knowledge, this is the first study utilizing organotypic slice culture methodology to 
investigate the effects of ischemic insult in brain, and the first to link cell viability with MMP activity 
in the absence of peripheral immune cell effects. Taken together, these data indicate that MMP-9 
expression is linked to the resident microglial response within the first 48 hrs after OGD, and 
selective targeting of gelatin-degrading MMPs, most importantly MMP-9, may be an avenue for 
therapeutic intervention to combat H-I neuropathies. 
 
Implications and Future Directions 
Lectican deposition is upregulated in various injury models (Beggah et al. 2005; Mayer et 
al. 2005; Vorisek et al. 2002). These proteoglycans are key components of the glial scar (Silver 
and Miller 2004). The glial scar, a dense aggregation of proteoglycans, astrocytes and microglia, 
restricts plasticity through the inhibitory properties of lecticans and contributes to 
neuroinflammation through immune cell activity. The present study first investigated the specific 
pathology that is associated with neonatal H-I insult, and sought to determine whether lectican 
deposition was associated with the various elements of injury and inflammation.  
In the P7 rat, exposure to H-I resulted in a neural sequelae characterized by the 
activation of reactive astrocytes, activation of cd11b – positive microglia/macrophages and 
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upregulated expression of MMPs. Neuroinflammation occurred within 24 hrs after the insult, the 
earliest endpoint examined in these experiments. The injury resulting from H-I was also 
progressive, as cavitary infarctions were seldom observed 4 days after H-I (P11) but were 
prevalent at later endpoints. This is an important feature of this model that is seldom mentioned in 
the literature. Consistent with this lesion profile, lectican deposition was elevated at later 
endpoints, indicating that these molecules aid in the formation and maintenance of glial scarring 
after neonatal H-I, consistent with their role in other injury models.  
Another feature of neonatal H-I injury is damage to developing white matter. Deep 
cerebral white matter injury has been attributed to the inherent susceptibility of pre-OLs. Because 
lectican expression is developmentally regulated primarily by OLs, we hypothesized that cleavage 
of lecticans by ADAMTSs results in the loss of structural stability or cell signaling, thus rendering 
pre-OLs vulnerable to ischemic injury. Although the reduced expression of versican coincided 
with reductions in O4, the putative pre-OL marker, we were unable to detect changes in the 
cleaved fragment of versican. Similarly, no changes in brevican or the ADAMTS-derived cleavage 
fragment of brevican were observed in white matter. These data were also supported by the in 
vitro experiments which showed that pre-OLs did not preferentially grow on proteoglycan 
substrate. Upon considering these results, there are two possible explanations for the reductions 
in lectican expression at P11. The first is that the reduced expression was a consequence of cell 
death. This seems likely upon considering the role of lecticans after injury and the increased 
expression in glial scar at later endpoints. Another explanation, however, is that lecticans are 
cleaved by some other endogenous enzyme. As lecticans are the major substrates for ADAMTSs 
in brain and constitute the majority of ECM, the other likely proteases responsible for lectican 
cleavage are the MMPs. Indeed, MMP-9 expression was upregulated in the cerebral cortex and 
several white matter regions 24 hrs after insult. However, we did not detect alterations in 
cleavage fragments at the predicted molecular weights of those that would be produced from 
MMP proteolysis. Therefore, this scenario also seems unlikely.  
Despite this fact, MMP activity has been implicated in several pathologies and is known 
to activate proinflammatory cytokines and contribute to blood brain barrier degradation via the 
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cleavage of basement membrane components. Additionally, previous studies with rodents have 
shown that inhibition of MMPs can improve the neuropathological and behavioral outcomes after 
ischemia. Importantly, most treatments have been administered prior to or immediately after 
insult. Although the initial injury occurs in large part from glutamate toxicity and oxidative stress, 
neuroinflammatory processes contribute to delayed cell death. Due to the fact that neural injury is 
progressive and early diagnosis is difficult, therapies that target the delayed immune response 
may prove clinically relevant in treating H-I – induced neuropathies. The involvement of 
neuroinflammatory processes and MMP activity in ischemic pathology, coupled with the growing 
need for alternative therapies, led to the second series of experiments that tested whether 
administration of an anti-inflammatory or MMP-inhibitory compound at a delayed time point could 
neuroprotect.  
AG3340, a small molecule hydroxamate-based MMP inhibitor, exhibits high selectivity for 
gelatinases and demonstrates good oral bioavailability in rat (Santos et al. 1997). A previous 
study showed that this compound attenuated white matter injury in the adult rat brain when 
administered just prior to chronic cerebral hypoperfusion (Nakaji et al. 2006). Minocycline has 
also been shown to possess MMP-inhibitory properties (Machado et al. 2006) but acts primarily 
as an anti-inflammatory agent. This compound has also demonstrated neuroprotective effects 
after H-I in the rat neonate, including reductions in white matter injury and neurodegeneration 
(Cai et al. 2006), and improved behavioral outcomes (Fan et al. 2006). In these experiments, 
efficacy was achieved when the drug was administered 12 hrs prior to the insult and again 
immediately following the insult. Consistent with the protective effects of these compounds shown 
previously, we showed that both minocycline and AG3340 conferred neuroprotection when 
administered 24 hrs after H-I. Both compounds were effective in reducing neurodegeneration, 
astrogliosis and immune cell recruitment. Of interest, cd11b – positive microglia/macrophages 
were greatly reduced compared to vehicle alone, indicating that the recruitment of immune cells 
to the lesion site had been disrupted. 
In the organotypic slice, both AG3340 and minocycline were efficacious in attenuating 
OGD – induced neurodegeneration. Furthermore, increased gelatinase activity correlated with 
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increased neurodegeneration, and both compounds were effective at reducing gelatinase activity 
as well. Data from these experiments also revealed an altered expression profile for MMP-9. 
Slices exposed to OGD upregulated MMP-9 expression in microglia, as identified with the 
microglial marker cd11b, and this colocalization was not observed in slices exposed to normoxia. 
Taken together, these data demonstrate a direct link between gelatinase activity and the 
inflammatory response to H-I. While the effects of AG3340 indicate that the selective inhibition of 
active MMP-9 and/or MMP-2 is sufficient to significantly reduce neurodegeneration in the 
absence of the peripheral immune system, the fact that minocycline was equally efficacious 
supports the notion that the resident immune cell response may be intimately connected with 
MMP expression or activation.  
It is important to note that both minocycline and AG3340 showed efficacy in the ex vivo 
model at concentrations equivalent to the doses administered in the in vivo experiments. In vivo, 
administration of these compounds ameliorated the recruitment of cd11b - positive microglia or 
macrophages, reduced astrogliosis and decreased neurodegeneration 7 days after H-I, beginning 
24 hrs after the insult. This is a critical distinction from previous reports that began treatment prior 
to or immediately following the insult, thus making the present data attractive in terms of potential 
clinical relevance. Collectively, the data from the in vivo and ex vivo models provides several 
insights into the ways in which neuroinflammation and MMP activity contribute to 
neurodegeneration after H-I. The in vivo experiments consisted of a 6 day treatment period that 
primarily targeted the delayed immune response. Additionally, it could not be determined whether 
cd11b – positive cells were of CNS origin, as there is currently no commercially available 
antibody that differentiates between resident microglia and peripheral macrophages.  
The present study exploited a model that lacks peripheral immune cell responses and 
demonstrated that heightened MMP activity is associated with neuronal cell death during the 
early neuroinflammatory response to H-I. This model is also advantageous in that it is more 
conducive to mechanistic experimentation and more closely resembles the microenvironment in 
brain when compared to primary cell culture or mixed-glial culture. The fact that these 
experiments were performed on intact slices from neonatal rat brain, using drug concentrations 
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equivalent to in vivo doses from the previous experiments, further strengthens comparisons 
between the outcomes. An important difference with the slice culture experiments, however, is 
that these compounds were added to the media immediately prior to OGD exposure, which 
occurred for 48 hrs. Therefore, this model mainly assessed the early response to ischemic injury, 
whereas the in vivo study targeted the delayed immune response.   
Previous studies have demonstrated that gelatinase upregulation is associated with blood 
brain barrier degradation (Cunningham et al. 2005; Manicone and McGuire 2008; Rosenberg and 
Yang 2007). Both peripheral and resident immune cells may contribute to cell death through 
inflammatory signaling, yet the relative contributions of infiltrating leukocytes and resident 
microglia have not been investigated in detail. Results from the present study show that resident 
microglia upregulate MMP-9 after OGD in intact brain slices, and that increased gelatinase 
activity and neurodegeneration are attenuated after treatment with AG3340. These data clearly 
demonstrate that gelatinase activity is likely connected with the early neuroinflammatory response 
in brain after H-I.  
 The present study showed that MMP inhibition is protective in the absence of peripheral 
leukocytes. This suggests that these proteases may enhance the inflammatory response through 
mechanisms other than blood brain barrier degradation. One candidate mechanism is “sheddase” 
activity, in which MMPs proteolytically cleave and activate cell surface cytokines, chemokines and 
apoptotic death receptors. Thus, gelatinase activity may facilitate cytokine release, alter 
chemokine gradients and/or initiate apoptosis through the extrinsic pathway. Several cytokines 
and chemokines have been identified as substrates for gelatin-degrading MMPs. Previous studies 
have shown that gelatinases process and activate TNF-α (Gearing et al. 1994) and IL1-β 
(Schonbeck et al. 1998), both of which are elevated after ischemia and are thought to contribute 
to cell death. The perinatal brain also expresses high levels of apoptotic enzymes, including 
caspase-3 (Hu et al. 2000), APAF-1 (Ota et al. 2002), Bax (Vekrellis et al. 1997) and Bcl2 (Merry 
et al. 1994). In fact, some data suggests that apoptosis is the primary mechanism of delayed cell 
death in the rat neonate after ischemia (Northington et al. 2001). TNF-α triggers apoptosis 
extrinsically through the activation of TNFR1. Thus, cleavage of TNF-α by gelatinases may be an 
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important event leading to cell death. Similarly, cleavage of FasL from cell surfaces could 
increase apoptotic activity depending upon the specific microenvironment (Wetzel 2005). There is 
data indicating that MMP-3 (Powell et al. 1999) and MMP-7 (Ethell et al. 2002) process FasL into 
an activated soluble form, yet the overall effects on apoptotic activity depend upon the cell type. 
To date, there is a paucity of data as to whether gelatinase cleavage of death receptors or death 
receptor ligands occurs in vivo after H-I.  
MMPs may also exacerbate the inflammatory response through proteolytic cleavage of 
SDF-1α and various MCP chemokines, including MCP-1 (Overall et al. 2002). Another group 
showed that SDF-1α stimulated gelatinase expression and MMP-9 activity, specifically, in a HeLa 
cell line. These effects were associated with increased ectodomain shedding of syndecan 1 and 
syndecan 4 that was not dependent on the SDF-1α receptor CXCR4. Additionally, RNAi silencing 
of MMP-9 resulted in reduced cleavage of syndecan 1 and syndecan 4, demonstrating a major 
role for MMP-9 in SDF-1α – mediated syndecan shedding. Expression of syndecans is high in 
cerebral vasculature, and these proteoglycans modulate transendothelial migration of monocytes 
across the brain endothelium (Floris et al. 2003). In the context of the present study, this 
mechanism would be consistent with the in vivo experiments where minocycline and AG3340 
ameliorated microglia/macrophage migration to the injured cortical lesion site. Future studies 
aimed at defining the early time course for efficacy in vivo, as well as the specific pro-
inflammatory molecules and immune cell types involved in this response, are critical not only to 
elucidate the specific sequence of neuroinflammatory events that contribute to H-I injury, but also 
to develop effective therapeutics that can be administered at clinically relevant time points. 
 
.  
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Figure 1 Legend 
ECM lecticans and gelatin-degrading MMPs contribute to neonatal H-I injury through 
multiple mechanisms. Necrotic cell death after H-I leads to blood brain barrier degradation, 
reactive astrogliosis and activation of resident microglia. Lecticans are deposited into the ECM in 
response to injury and contribute to glial scar formation, thus forming a barrier between injured 
and viable tissue that restricts cell migration into the lesion site. Immune cells of the brain 
increase expression and secretion of proinflammatory cytokines and chemokines. Gelatinase 
activity initiates a second, delayed opening of the blood brain barrier through proteolytic 
processing of basement membrane constituents. Peripheral macrophages infiltrate into the brain 
and further promote the immune response. Gelatinases may also activate cytokines and 
chemokines through sheddase activity. Ultimately, this feed-forward neuroinflammatory response 
potentiates apoptotic signaling and creates unfavorable conditions for neuroplasticity and repair. 
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Figure 2 Legend 
Inhibition of gelatin-degrading MMPs reduces the inflammatory response and improves 
the neuropathological outcome after H-I in the rat neonate. Gelatinase inhibition is 
neuroprotective after H-I both in vivo and ex vivo. Treatment with AG3340 or minocycline 
significantly reduced neurodegeneration when administered 24 hrs after H-I. Additionally, these 
compounds ameliorated immune cell recruitment to the cortical lesion site. Organotypic slices 
exposed to 48 hrs of OGD in media containing these compounds also showed reduced 
neurodegeneration, effects that were associated with reduced gelatinase activity. Neuroprotection 
may occurs through several mechanisms. Gelatinase inhibition likely preserves the integrity of the 
blood brain barrer, restricting entry of peripheral macrophages into the brain, and may dampen 
microglial activation or migration to injured sites. Additionally, inhibiting gelatin-degrading MMPs 
could alter cytokine and chemokine signaling, thus attenuating neuroinflammation and apoptosis. 
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Supplemental Figure 1 
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Supplemental Figure 1 Legend 
Activated microglia/macrophages recruit to hippocampal lesion site 24 hrs after H-I. Rats 
were exposed to H-I at P7 and sacrificed 24 hrs after insult. Micrographs show intense ED-1 
immunoreactivity in the ipsilateral hippocampal dentate gyrus (B,D) compared to the contralateral 
control regions (A,C). CD68 expressing cells exhibit an amoeboid morphology consistent with 
activated microglia and macrophages.  
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Supplemental Figure 2 Legend 
MMP-9 expression increases 24 hrs after H-I. Rats were exposed to H-I at P7 and sacrificed 
24 hrs after insult. Micrographs show increased MMP-9 immunoreactivity in the ipsilateral 
cerebral cortex (B), external capsule (D), corpus callosum (F) and corpus striatum (H) relative to 
respective contralateral control regions (A,C,E,G).  
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